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ABSTRACT
Herpes simplex viruses (HSV) infection is a common cause of ocular disease
and can result in a chronic inflammatory reaction that impairs vision. This
latter manifestation is called herpetic stromal keratitis (HSK) and usually
occurs as a consequence of virus reactivation from latency in the trigeminal
ganglion. The pathogenesis process involves complex interactions of cellular
and molecular events. HSK in humans, and certainly its murine experimental
model, appears to be an immunopathologic disease process. The crucial cell
type orchestrating the inflammation is a CD4+ Tcell that has a Thl cytokine
producing profile. However, prior to this immunoinflammatory phase,
multiple events occur that set the stage for subsequent pathology. These
include production of cytokines and chemokines, infiltration of innate immune
cells and neovascularization of the avascular cornea.
Current understanding about human and murine HSK pathogenesis is
reviewed in Part I. Part II progresses this knowledge using knockout and
transgenic mice. Results in Part II clarify the essential role of IL-l, a
proinflammtory cytokine, produced as a consequence of virus replication, in
HSK pathogenesis. Part III, in addition to Part II, elucidate the mechanisms
involved in IL-l and IL-6 mediated polymorphonuclear leukocyte (PMN)
influx and neovascularization of cornea following virus infection. These
cytokines were shown to be produced quite early after infection and capable of
inducing angiogenic factors, resulting in angiogenesis of the cornea. In
addition, the role of IL-l in inducing proinflammatory arachidonic acid
metabolites has been discussed in PART IV. Cycloxygenase 2 enzyme
iv

produced from resident corneal cells in presence of IL-l was shown to be
crucial for creating an inflammatory milieu and facilitate early PMN influx in
murine cornea. These results provide novel insights into the link between viral
infections, pro-inflammatory mediators, PMN migration, angiogenesis and
HSK development. Our understanding about the role of IL-l in HSK
pathogenesis was evaluated clinically in Part V using an IL-l receptor
antagonist (IL-l ra) protein. Mice receiving IL-l ra

h~d

diminished disease

severity. The administration of IL-l ra was shown to reduce the influx into the
cornea of cells of both the innate and adaptive immune response. In addition,
the treatment also diminished corneal VEGF levels resulting reduced
angiogenic response. Our results show the iluportance of targeting early
proinflammatory molecules such as IL-l to counteract HSK and advocate IL-l
ra as an effective agent to achieve this. In Part VI, a novel flow cytometry
based assay has been used to quantify corneal angiogenesis following ocular
HSV infection. Our results indicate that, this assay was sensitive enough to
able to pick up the difference in angiogenic response between mice. Thus,
estimation of angiogenesis on the basis of number of endothelial cells proved
to be a useful approach to quantify corneal neovascularization.
This dissertation presents research aimed at elucidating both molecular
and cellular events in HSK pathogenesis. These results will serve as guidelines
for future development of more efficient prophylactic and therapeutic
strategies.
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Information provided in this chapter is a slightly modified version of a review
article accepted for publication in the Microbes and Infection published by
Partha Sarathi Biswas and Barry T. Rouse.

Biswas, P. S., and B. T. Rouse. Early events in SK pathogenesis- setting the
stage for a blinding disease. Microb. Infection. In press.

My contributions in this review include (1) selection of the topic (2)
compilation of information data analysis and interpretation (3) plan review
outline (4) writing (5) preparation of figures and manuscript editing.

INTRODUCTION
On the basis of the fact that 80% or more of the adult human populations may
be sero-positive for herpes simplex virus (HSV), this virus must be judged as a
highly successful pathogen. Furthermore, the virus kills very few patients and
most who suffer lesions recover without significant conlplications. However,
when the eye becomes the site of infection, a chronic immuno-inflammatory
syndrome may result that impairs vision (1). Such herpetic stromal keratitis
(SK) lesions represent the commonest infectious cause of blindness in the
western world. It is estimated that in USA, 400,000 persons are affected, with
20,000 new cases of SK occur annually; the incidences ranges from 4.1- 20.7
cases/100,OOO patient years (2). In humans, SK is usually the sequel to

recurrent infection following reactivation of virus from the trigeminal
ganglion (1). The pathogenesis of human SK is considered to involve T cell
2
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mediated inflammatory events, a notion strongly supported by experimental
studies in a mouse model (1, 3, 4, 5). In this model, the lesions are mainly
orchestrated by CD4+ T cells (4, 5) although the identities of target antigens
that drive such cells remain ill-defined. In addition, several events occur in the
infected eye prior to the onset of clinically evident SK. Since such events may
be subject to manipulation and the control of lesion severity, understanding
early events represents an important objective for SK research. This review
describes recent work from our laboratory and others, which defines multiple
pathogenic mechanisms ongoing during the early phase of SK in the mouse
model. We also comment about what is understood about the clinical phase of
SK.

VIRUS ENTRY IN THE CORNEA
Following primary infection, herpes viruses reaching the surface of the eye are
initially suspended in the ocular tear film. The key feature of ocular surface
innate resistance is the constant bathing of the ocular surface by tears
produced from the lachrymal gland. Thus molecules, cells and infectious
agents reaching the ocular surface may be washed away quickly and
effectively. In addition, virus infections are vulnerable to a number of
substances with antiviral activity present in tears. These include lysozyme,
immunoglobulin A antibody, complement, lactate dehydrogenase, amylase
and peroxidase. Interferons, particularly alpha and beta types also occur in
tears during a viral infection of the ocular surface (6- 9). The intact corneal
epithelial cell layer may act as an effective physical barrier to infection by
3

microorganisms, and its outer terminally differentiated cells may be refractory
to infection, such as by HSV (10). However, whereas this broad spectrum of
defenses limits the chance of infection, agents such as HSV do establish
infection usually in the epithelial layer of the cornea (11).
Successful infection by HSV induces several key events that relate to
the subsequent development of ocular pathology. One such event, which in
fact does not require progeny virus production, is entrance into sensory nerve
terminals in the corneal epithelium. Virus then travels by retrograde transport
to the neuronal cell bodies in the trigeminal ganglia (TO) (12, 13). Using a
LACz encoding virus, Hill and colleagues demonstrated that, virus can reach
the TO within 24 hrs of ocular infection irrespective of the viral dose used
(14). In the TO, virus either replicates usually killing cells, or enters into an
alternative replication mode called latency which may persist in cells
indefinitely (13, 15, 16). It is also conceivable that viruses may undergo a
productive cycle but this is contained in some way 'by signals from immune
cells, primarily CD8+ T cells (17, 18), [19]). While the latent state, which may
involve 100 more copies of the viral genome, may be permanent in many
cells, in others it is terminated in response to a variety of stimuli (15, 16).
When this occurs virus reenters into the productive cycle, and progeny virus
passes anterograde along nerve exons to produce a recurrent bout of virus
replication at the initial site of infection (13, 15). Such recurrences may be
subclinical or clinical and in the eye may either give rise to secondary lesions
in the epithelium or cause a chronic inflanlmatory reaction in the underlying
stroma.
4
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The stromal inflammatory reaction occurs in around 20% of human
cases and this is the lesion that is mainly responsible for vision impairment
(2). The lesion is judged to largely represent a T cell mediated immuno
inflammatory event, but details of the pathogenesis are poorly understood (3,
4). Thus it is not clear if virus itself enters the stroma and if so whether this
spreads from the infected epithelial site or arrives via axonal passage from the
TO.

Moreover, although T cells form a prominent part of the stromal

response, the nature of target antigens that are being recognized remain to be
identified. Most of our understanding of the pathogenesis of SK comes from
experimental studies in the mouse where the lesions regularly occur as a
sequel to primary infection. Shnilar lesions can occur by induced reactivation
(20), but this perhaps more relevant model, is difficult to establish and occurs
in only a minority of animals. Our description of events in the stroma that
result in the chronic blinding immuno-inflammation applies to the primary
disease model and when known the natural human disease.

VIRUS AND EARLY INFLAMMATORY EVENTS
Inflammatory cells
Following virus infection of the corneal epithelium, a prominent infiltrate of
inflammatory cells, primarily consisting of neutrophils (PMN) (21), occur into
stromal tissues subjacent to the infected epithelium (See Fig 1) (Note all figure
in appendix). The cells escape from the limbal vessels presumably in response
to signaling molecules generated from virus infected cells. This response starts
around 18 hr post infection (p. i.), peaks at 48 hr p. i. and then declines such
5

that by 5 days after infection it is barely evident (21). This pattern of events
correlates with the duration of virus detection and it seems that PMN may be
responsible for viral clearance (21, 22). Thus depleting PMN with specific
monoclonal antibodies resulted in delayed viral clearance from the cornea. It is
not clear how virus, which is predominantly in the epithelium, is cleared by
the mainly stromally located PMN. Ideas for the mediation of such defenses
include TNF-a, nitric oxide and reactive oxygen metabolites production by
PMN. Evidence for this comes from studies where corneal neutrophils were
shown to produce these factors by in situ hybridization techniques (23).
The stromal PMN response may have other consequences. For
example, factors released following PMN degranulation resulted in tissue
destruction which may unmask corneal autoantigens. One of these factors is
NO (24). Polymorphonuclear leukocytes as well other cells in the early
response, also contribute to the ongoing inflammatory process by producing
proinflammatory cytokines such as

IL-1~,

TNF-a, IL-8 and IL-12 (23), thus

setting the stage for the subsequent chronic immunoinflammatory phase.
Crucial components of PMN include a source of preformed VEGF (25), as
well as the tissue degrading enzyme matrix metalloproteinase-9 (MMP-9)
required to breakdown the stromal matrix (26). Both molecules are involved in
the neovascularization which results from HSV infection (discussed later) (26,
27) (See Fig 2).
Although PMN dominate the early inflammatory phase, other cell
types can also be demonstrated in the stroma. These include macrophages
(28), dendritic cells (DC) (29, 30), natural killer cells (NK cells) (31, 32) and

6

yo T cells (33).

NK cells and macrophages likely also participate in corneal

virus clearance and can also act as a source of cytokines, chemokines and
angiogenic factors (28, 31, 32). In line with this notion, depletion of NK cells
and macrophages following ocular HSV -1 infection resulted in more severe
SK (28, 31, 32). Another prominent feature of the injured cornea, including
that caused by HSV, is the invasion of Langerhans DC, likely from the
conjunctiva, into the cornea (29, 30). However this event takes several days to
occur. Presumably, such cells also act as a source of cytokines and
chemokines but their major function in SK pathogenesis is probably to
transport viral antigens to lymphoid tissues where the adaptive immune
response is initiated (discussed later). However, recent findings by Carbone
group question the role of Langerhans cells for antigen presentation. They
contend that such cells pass on viral proteins to other subsets of DC which
process Ag by cross priming and present antigen to CD8+ T cells (34). At
present the respective roles of these numerous nonlymphoid inflammatory
cells in the early response to HSV remains unresolved. Thus past observations
have focused on a single cell type and usually ignored the role of others. One
suspects that a large measure of cell to cell interaction could be occurring.
This could include regulatory effects mediated by natural regulators such as
NKT cells. Such effects have been noted to occur in the anterior chamber (35),
but have yet to be investigated in the cornea.

7

Cytokines
HSV infection of the cornea causes the expression of multiple proteins
associated with the inflammatory response. Among the numerous cytokines
that are produced IL-1 and IL-6 are prominent and these may be pivotal in
starting the cascade of events that results after several days in stromal lesions
(36, 37). When HSV productively infects a cell, most host gene expression is
turned off (38). Nevertheless infected cells are stimulated to produce IL-1 and
IL-6 at least for a time and this may represent their major initial source (39
41). However, it is evident that uninfected cells ultimately become the major
cell source of cytokines. It is not clear how the uninfected cells are induced to
produce cytokines but one viable idea is that pathogen associated molecular
patterns (PAMPS) expressed by virus infected cells, or perhaps extracellular
virus itself, could bind to Toll-like receptors (lLR) on cells and cause them to
synthesize and secrete cytokines and other inflammatory mediators. With
respect to HSV, there is evidence that the viral DNA may have lLR-9
stimulating activity (42) although there may be insufficient extracellular viral
DNA present in vivo to subserve that function. Furthermore, recently HSV
was proposed to have lLR-2 binding activity although the viral components
responsible for this await identification. At least in the central nervous system
(eNS), it seems that HSV, via its lLR-2 activating property, may cause IL-6
production as well as other mediators (43). We are investigating this issue in
the cornea where we anticipate that lLR-2 binding may be a critical stimulus
for IL-l production.

8

Whereas PAMPS may be important for initiating the inflammatory
protein cascade, it also seems likely that the initial cytokines induced are also
involved in driving the expression of other key molecules. Thus IL-I can
cause IL-6 production from uninfected epithelial cells (44), and IL-6 is known
to induce macrophage inflammatory protein-2 (MIP-2) (CXCL8), likely a key
molecule for PMN recruitment in the stroma (45, 46). This issue has been
extensively studied by us and others using IL-6-/- mice (46), CXCR2-/- mice
(47) and neutralization of MIP-2 using specific monoclonal antibody (45). In
all these studies PMN ingress to the corneal stroma was shown to be severely
compromised (45-47). In addition, IL-I was also shown to influence PMN
migration and via its stimulation of IL-6 expression (44). In line with this
observation, mice transgenic for the IL-I receptor antagonist protein showed a
diminished early inflammatory response (48).
In addition to IL-6, another factor known to be upregulated in corneal
stromal cells following IL-I stimulation is Cycloxygenase-2 (COX-2) (our
unpublished data). COX-2 induced proinflammatory prostanoid synthesis such
as prostaglandin E2 (PGE2) can cause PMN invasion in various inflammatory
models (49). Corneal fibroblasts may act as a major cellular source of COX-2
(our unpublished data). Possible agonists that drive COX-2 production at an
early time point include proinflammatory cytokines such as IL-1 ~ and TNF-a
(our unpublished data). Thus blocking COX-2 activity at an early time point
with a specific COX-2 inhibitor diminished PMN influx and resulted in less
SK severity (our unpublished data). Another cytokine known to be
upregulated following ocular HSV infection is TNF-a (50, 51). Recent studies

9

have demonstrated that TNF-a-I- mice were more susceptible to acute corneal
HSV-1 infection than controls, as manifested by an increased ocular virus
titers and mortality rate (51).
Another early cytokine event that may be pivotal in the pathogenesis of
SK is IL-12. Our group was the first to demonstrate that a viral infection may
cause IL-12 production (52). Using a sensitive radioimmunoassay, IL-12
transcripts were detected in HSV infected corneas as early as 1 day p. i., with
peak levels around day 3 p. i. and sustained production until at least day 22 p.
i. (52, 53). That IL-12 production is an important event was best shown by the
observation that both p35-1- and p40-1- mice develop only mild lesions of HSK
(54). However, it is still unclear how HSV infection induces IL-12 production.
The best evidence is that the event is largely a paracrine one (53) but the
identity of the stimulus for IL-12 production by uninfected cells remains to be
identified.

Possible mediators

under

consideration

include

cytokines,

chemokines, stress proteins, and viral products released from infected cells.
With regard to the latter, virions themselves would seem to be unlikely
candidates, as UV -inactivated virus and fixed cells expressing viral proteins
caused only minimal IL-12 induction (53). Another candidate could be viral
DNA, a source of DNA rich in potentially bioactive CpO motifs known to be
potent IL-12 inducers (55), but such issues await confirmation. The
inflammatory cells such as PMN and macrophages, but not corneal resident
cells, are the likely source of IL-12 following viral infection (23, 53).

The cytokine IL-12 has several downstream effects that have impact
on SK pathogenesis. These include production of IFN-y by cells with IL-12

10

receptors. Although not proven in eye, the most likely cells that respond and
produce IFN-y are NK cells, macrophages and neutrophils. Removal of each
cell type may compromise the ability to clear virus from the cornea and CNS
(22, 28, 31). Furthermore, IL-12 transgenic mice clear virus quickly by
upregulating IFN-y production in the cornea (56, 57). Previous observations
suggest the role of STAT 4 dependent pathway in the production of IFN-y
following IL-12 stimulation (57). Supporting this scheme we were able to
demonstrate that STAT4-/- mice have lower levels of IFN-y in the cornea
following virus infection (our unpublished data). Whatever the source of IFN
y is, this molecule appears to be pivotal in antigen processing as well as other
events in HSK pathogenesis. These include aiding PMN influx in the corneal
stroma by up-regulating PECAM-l (Platelet endotholelial cell adhesion
molecule-I) expression on vascular endothelial cells (9). Conceivably,
neutralization of PECAM-l or IFN-y resulted in diminished PMN ingress (9).
In addition, in vitro stimulation of human corneal epithelial cells with IFN- y
caused upregulation of ICAM-l expression, another cell adhesion molecule
responsible for adhesion and extravasation of inflammatory cells (58). IFN- y
also upregulates MHC II expression on antigen presenting cells (APC)
involved in the induction of antigen specific CD4+ T cells in the draining
lymph nodes (59). Interestingly, murine stromal fibroblasts can express MHC
II and present antigen following stimulation with IFN- y (60). On the other

hand, IFN- y could help modulate lesion development since it also induces
angiostatic chemokines such as IP-I0 (CXCLI0) (61). Thus, IL-12 and IFN- y
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response to HSV infection indirectly impacts on both inflammatory and
regulatory effects during SK.
Another cytokine that deserves attention in SK pathogenesis is IL-I7.
Recent work by the Verjans group has demonstrated the presence of IL-I7 and
its role in PMN influx in human SK (62). In this report, IL-I7 was shown to
influence PMN infiltration through upregulation of IL-6 and IL-8 (62). In
addition IL-I7 might stimulate VEGF production and aid in the angiogenesis
process (63) (discussed later). However, the cellular source as well as the
stimulus of IL-I7 in infected corneas remains ill-defined. One possibility is
IL-23, which is well known to induce IL-I7 from a variety of cell types in
various inflammatory models

(64)~

Usually IL-23 acts to induce IL-I7 in

lymphocytes, which in the HSV infected cornea, do not enter the cornea until
6-7 days p. i. (64). However since IL-23 and IL-I7 producing CD4+ T cells
were shown to be crucial events in some other chronic inflammatory
conditions, their role in various stages of herpetic keratitis merits further
investigation.
Much remains to be established with regard to cytokine expression and
function during the early phase of ocular infection with HSV. One crucial step
for the pathogenesis of SK that is initiated early after infection is
neovascularization of the normally avascular cornea. As is discussed later,
several cytokines may participate in the angiogenesis process by acting as
stimulants for the induction of angiogenesis factors; some cytokines, however,
may exert antiangiogenic activities (See Fig 2).
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I

Chemokines
Following viral replication in the epithelial layer, several chemokine mRNAs
are promptly upregulated in the cornea (65, 66). The fact that viral replication
for an initial few days is essential has been established by showing feeble
chemokine responses if virus was neutralized with antibodies (65) or corneas
were infected with UV inactivated or replication incompetant mutant virus
(67). The cellular source of chemokine and the nature of the induction stimuli
remain ill-defined. Cells infected by the virus are the most logical candidate
source, but once virus replication is well underway in a cell, host cell mRNA
is curtailed (38). Some evidence does exist however, that the viral immediate
early protein ICPO is all that is necessary to induce chemokines expression
(67). An alternate cellular source is the nearby corneal resident cells as well as
inflammatory cells that are exposed to products from HSV infected cells. This
issue of cellular source of various chemokines in HSV infected eye must await
the refinement of approaches such as in situ hybridization and double color
ilnmunohistochemistry to study this topic.

Early after HSV infection CXC chemokines such as MIP-2 and KC
(CXCL3) were shown to predominate (65, 67). In addition MCP-1 (CCL2),
RANTES (CCL5), IP-10 (CXCL10) was also present (65). Recently one group
demonstrated that corneal epithelial cells and stromal keratocytes express
MIP-3a (CCL20) mRNA and protein following ocular HSV -1 infection (68).
Despite the representations of multiple chemokine during early HSV infection,
some studies do indicate that single chemokines may be crucial for SK
pathogenesis. Thus the Lausch group demonstrated that neutralization of the
13

CXC chemokine MIP-2 markedly suppressed the initial PMN influx (45).
Even more significant suppression was obtained when both K-C and MIP-2
were neutralized together (45). These observations were in fact supported by
our own finding using CXCR2-/- mice.

These mice demonstrated

significantly reduced PMN invasion at an early time point (47). However, the
induction stimulus for these chemokines seemed to be proinflammatory
cytokines produced as a consequence of virus replication in the corneal
epithelium. We also know that IL-6 promotes MIP-2 production from resident
cells in an autocrine- paracrine manner (44). In addition, corneal epithelial
cells and stromal cells produce CCL20 following stimulation with IL-l ~ and
TNF-a (68). It will be important to determine what functions chemokines such
as these are playing during the early phase. One possibility is that they serve to
attract inflammatory cells that in turn also act as a source of chemokines.
An additional group of chemokines that lacks expression during the
early inflammatory phase but are expressed during late preclinical phase are
MIP-1 a (CCL3) and lymphotactin (XCL1) (67). What causes upregulation of
these is not known, but they are likely responsible for CD4+ T cells influx
during the clinical phase. Supporting this notion Lausch and his colleagues
demonstrated that MIP-1 a-/- mice fail to show the secondary inflammatory
cell influx and do not develop SK (69). In addition, neutralization of MIP-1a,
or the application of 1L-10 which abrogates MIP-1 a production, resulted in
diminished SK severity (70). However mechanistic explanations for these
observations have not been provided. Another unresolved issue in SK
pathogenesis includes an explanation for the markedly preferential invasion by
14

CD4+ T cells versus CD8+ T cells to the infected cornea. This issue is
currently under investigation in our laboratory (discussed later).

VIRUS AND ANGIOGENESIS
One characteristic of HSV induced immunopathology is neovascularization of
the cornea, an event shown necessary for SK pathogenesis (27). Whereas the
normal cornea is avascular, in SK new blood vessels sprout from limbal
vessels by day 1 p. i. reaching the central cornea by day 20 p. i. (71).
Inflammatory cells readily escape from these highly permeable neovessels,
giving rise to haze and vision impairment. Indeed neovascularization
anywhere along the visual axis may impair vision, with vessel removal being
highly problematic.
Although the cornea has been a favorite tissue to study angiogenesis,
the

identity

of

specific

angiogenic

factors

involved

in

corneal

neovascularization associated with HSV replication remains in its infancy.
Curiously HSV replication in the epithelium results in angiogenesis in the
underlying stroma. Furthermore unlike some other viruses, most notably
human herpes virus 8 (72-75) and Orf virus (76), HSV appears not to encode
proteins which are themselves directly angiogenic. In consequence, the means
by which HSV infection results in angiogenesis likely involves a cascade of
cytokine mediated or other paracrine events. These events in tum are assumed
to cause expression of one or more proteins directly involved in angiogenesis.
Our group has gathered support for these ideas. We have shown, for example,
that HSV infection is followed by the expression of several known
15

angiogenesis factors in the cornea. These include Vascular endothelial growth

of the pathogenesis, with VEGF transcripts detectable by 12 hr p. i. and

I
It

proteins by 24 hr p. i. (71). Such observations imply a role for VEGF in HSV

t

induced angiogenesis; a notion supported by the fact that treatment of mice

t

factor (VEGF) (71), basic Fibroblast growth factor (bFGF) (our unpublished
data), Matrix metalloproteinase 9 (MMP-9) (26) and E-L-R motif containing
chemokines (47, 65, 67).
In SK, VEGF mediated angiogenesis is a prominent and early feature

with a VEGF inhibitor resulted in reduced HSV induced angiogenesis (71). In
addition, turning off VEGF and VEGF receptor 2 gene expressions using
small interfering RNA (siRNA) resulted in diminished angiogenic responses
following virus infection (77). In consequence, these mice demonstrated less
severe SK (77). While looking for the cellular source of VEGF initially after
infection, uninfected corneal epithelial cells and stromal cells were shown to
be involved (71). However, with the infiltration of inflammatory cells, such as
PMN and macrophages, these cells act as an additional and perhaps the major
source of VEGF (71). Interestingly, the production of VEGF appeared to be a
paracrine effect of molecules released from virus infected cells, since
uninfected corneal cells and not infected cells stained positive for VEGF. As
seen in corneal tissue sections, the VEGF producing cells were close to
infected cells but were seldom infected themselves (71).

The above observations raise the question as to the mechanisms by
which HSV infection of a cell triggers another cell to tum on VEGF gene
expression. Although productive HSV infection, by virtue of its virion host
16
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t

shut-off protein, eliminates most host cell protein synthesis (38), evidence
suggests that some proinflammtory cytokine genes such as IL-l and IL-6 are
upregulated for a time in infected cells «39-41). These cytokines are known to
be potent stimulators of VEGF production (78-81). In addition, intrastromal
injection of IL-l and IL-6 results in corneal neovascularization in a VEGF
dependent manner, since neutralizing VEGF with a monoclonal antibody
resulted in a significant reduction in the angiogenesis process (44, 47).
Supporting this scheme, we could demonstrate that blocking IL-l with an IL-l
receptor antagonist protein resulted in compromised angiogenesis following
ocular HSV infection (48).
An additional paracrine stimulus for VEGF production may be HSV
DNA, rich in bio-active CpG motifs. Our group was the first to demonstrate
that bioactive CpG motifs can induce corneal angiogenesis by upregulating
VEGF, indicating an essential role for TLR-9 mediated signaling events (82).
However, the exact mechanism of VEGF upregulation is not fully understood.
One possibility is HSV CpG TLR 9 interaction induces a signal transduction
mechanism that proceeds through a MyD88 dependent or independent
pathway to activate various transcription factors such as NFk{3. An alternative
idea to explain this issue is that bioactive CpG ODN induces the production of
cytokines such as IL-l and IL-6, which in tum upregulate VEGF production.
Such notions await confirmation.
Since certain chemokines with E-L-R motifs are well known to have
angiogenic activity (83), these also represent likely candidates for induction of
ocular angiogenesis. One such chemokine known to be upregulated following
17

ocular HSV infection is MIP-2 (47, 65, 70). Curiously, other chemokines such
as some CXC chemokines lacking the E-L-R motif, may inhibit angiogenesis
(84). Some of the angiostatic chemokines exert their function by binding to
heparan sulphate on target cells (85). Interestingly, heparan sulphate is also a
molecule involved in HSV entry into target cells (86). Thus, it is conceivable
that HSV may bind heparan sulphate and block the angiostatic activity thus
driving the process towards angiogenesis. These issues are currently under
investigation in our lab.
Another molecular species involved in HSV induced angiogenesis was
the collagenase MMP-9, an enzyme that degrades the stromal matrix material.
MMP-9 has been associated with tumor angiogenesis (87, 88), but the first
evidence that MMP-9 contributes to corneal angiogenesis came from our
laboratory (26). The cellular source of MMP-9 was shown to be PMN, since
depletion of cells resulted in diminished MMP-9 levels in corneal extracts
(26). It appears that targeting MMP-9 production with for example siRNA can
result in diminished corneal angiogenesis (89). In addition to PMN, corneal
epithelial cells may produce MMP-9 in response to inflammatory cytokines

,

I

involved in the corneal angiogenesis process, evidence accumulates to indicate

II

that some cytokines such as IL-12 (61) and IL-18 (our unpublished data)

t

such as IL-l and TNFa (90).
While the majority of the proinflammatory cytokines are indirectly

inhibit corneal angiogenesis by downregulating VEGF expression. Thus

I

overexpression of these cytokines in the cornea following virus infection

I

resulted in diminished angiogenesis and less severe HSK (Lee et ai, 2002a)
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(61). It seemed that IL-12 and IL-IS through their inhibitory effect act as
negative regulators and keep the neovascularization process under a tight
control following virus infection.
As is well known in both the fields of ocular pathology and cancer
biology, it is easier to prevent angiogenesis than removing already established
blood vessels. Thus early targeting of the angiogenesis process is essential
because inhibition of neovascularization has no benefit in terms of HSK
lesions if the vascular bed has already developed (71). To achieve a
satisfactory level of angiogenesis inhibition, currently the best bet might be to
use a combination of approaches and a variety of angiogenic molecules need
to be targeted. These include direct inhibition of VEGF and MMP-9 using a
combination of the VEGF antagonist (mFlt-immunoglobulinG) (71) and the
Tissue inhibitor of metallo proteinase 1 (TIMP-l) (26) or indirectly control
angiogenesis by limiting inflammation using anti-inflammatory drugs such as
the IL-l receptor antagonist protein (4S) and COX-2 inhibitors (our
unpublished data). A promising new candidate for therapeutic applications is
the recently used siRNA targeted against various angiogenic factors in the
cornea (77). However a major constraint in all these approaches includes the
lack of effective corneal delivery systems. So far, practical methods to achieve
efficient corneal delivery of antiangiogenic molecules are not on hand, but
given the extensive level of investigation in this area of research, success is to
be anticipated.
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STROMAL KERATITIS - THE OUTCOME OF INFECTION
Following the early events described previously which usually include the
cessation of viral replication and the removal of readily demonstrable viral
antigens from the eye, lymphocytes and other inflammatory cells invade the
stroma producing clinically evident SK. This process usually begins 6-9 days
p. i. and the cellular responses are at their peak around 2-3 week p. i (91). Few
studies have followed lesions for long periods to note subsequent changes in
the inflammatory response. However observations on human lesions indicate'
that they usually fail to resolve spontaneously, and require prolonged
treatment with anti-inflammatory drugs (11, 92). The pathogenesis of SK
provides us with several unresolved questions. Among the most difficult to

t

explain is what drives the inflammatory reaction after the virus infection itself

t

appears to have been contained. Moreover, it is difficult, if not impossible, to
generate SK either with inactivated viral preparations or indeed with

,

I

nonvirulent mutant viruses (93). In our hands, replication by wild type viruses

I

is necessary for at least 2 days to induce SK (94). Furthermore, so far we have

t

been unable to cause SK by introducing antigen into the corneal stroma of

1

It seems that replicating virus is necessary to drive the array of early

I
I

events described previously which are essential for SK development.

1

However, neither replicating virus, nor as far as we can measure, persistent

1

animals with adoptively transferred antigen reactive T cells.

viral antigen in the cornea, is involved in driving the chronic immuno
inflammatory phase (93). Presumably, early events leave the corneal stroma in
a condition that attracts inflammatory cells with these recruits perhaps further
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activated to participate in tissue damage. We know that one step necessary for
this event to occur is neovascularization, driven by VEOF and other
angiogenesis factors (26, 27, 71). Moreover, new blood vessels induced by
VEOF are quite permeable and readily leak vascular contents. In the stroma,
this leakiness cannot be random, since the majority of inflammatory cells in
the site express homing molecules such as the integrin VLA-4 (95).

In

addition, in mouse SK lesions, inflammatory CD4+ T lymphocytes outnumber
CD8+ T cells (96). This observation cannot be explained by a failure of the
HSV infection to activate a CD8+ T cell population. In fact, at least in the
C57BL6 mouse, HSV infection activates a higher frequency of CD8+ than
CD4+ T cells, yet even in such mice demonstrating CD8+ T cells in SK lesions
are problematic (96). Furthermore, even adoptive transfers of transgenic CD8+
T cells that recognize viral antigen are difficult to demonstrate in the corneal
lesions (96). Curiously, viral specific CD8+ T cells are readily demonstrable in
other inflammatory reactions caused by HSV such as in the TO (97). Reasons
why CD8+ T cells sparsely infiltrate stromal lesions need to be found.
With regard to the CD4+ population that forms part of the SK lesions,
the spectrum of antigens such cells recognize remains unknown. We anticipate
that viral antigens are the targets for some CD4+ T cells especially early during
the reaction, although this point has not been confirmed. What is known is that
CD4+ T cells are needed to generate lesions (98, 99). Furthermore, the
inflammatory function of CD4+ T cells can be modulated by other subsets of
CD4+ T cells that exert regulatory function (95). This seemingly IL-10
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producing function is assumed to be viral antigen specific, but this issue has
also not been firmly established.
Clearly the role of viral antigen in driving specific CD4+ T cells in
stromal lesions requires further study. In fact using TCR transgenic mice on a
SCID or RAG background that were unable to recognize viral antigens, SK
could be induced in these mice although as in immunocompetent animals, this
only occurred following infection with replication competent virus (100, 101).
In these TCR transgenic models, even administrating the cognate antigen into
the cornea failed to induce SK. Hence in this model too, we are left with the
dilemma of explaining why it is necessary to administer infectious virus in
order to generate SK lesions. Conceivably, the T cells involved may recognize
a wide range of antigens which could include autoantigens unmasked in the
cornea by the inflammatory response.
One favored explanation to explain the pathogenesis of SK is that the
lesions may be initiated by viral damage but subsequently they become
autoinflammatory (102) (See Fig 3). This concept explains that the virus
replication some how unmasks autoantigens in the eye and additionally
stimulates an antiviral T cell response that is cross-reactive with the corneal
autoantigens. The best evidence for this notion comes from the Cantor
laboratory, which maintains that the UL6 protein of HSV acts as a molecular
mimic for a corneal auto-peptide (103). This provocative hypothesis has not
been independently confinned and our laboratory and others have raised
questions about the interpretation (104). Indeed molecular mimicry as an
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explanation for an association between virus and any autoimmune disease has
been difficult to prove.
If molecular mimicry is not an explanation for SK pathogenesis,

conceivably some form of sustained bystander activation of T cells could be
involved. However currently this intriguing notion lacks a mechanistic
explanation of where and how such bystander activation takes place. One
possibility is that inflammatory molecules produced as a consequence of
ocular HSV infection activate the T cells in a non TCR mediated manner (See
Fig 4A). This idea is supported by the observation that it is possible to develop
lesions identical to HSK in animals whose T cells are genetically incapable of
recognizing viral antigens (94, 105). In these models, the chronic source of
activating cytokines was cells dying of HSV infection. In this instance, virus
persisted and spread to the stromal tissue location in some way (94, 101). We
have hypothesized that, this continually replicating virus in the corneal stroma
acts, possibly by TLR ligand activity, as the chronic stimulus for cytokine
Ichemokine production that in tum activates the incoming T cells. Such cells
then produce inflammatory mediators which participate in tissue damage.
The conclusion is that the stromal viral persistence is necessary, but the
mechanistic explanation for the source of virus is controversial. The
possibilities include direct cell-to-cell spread from corneal epithelium to
stroma or virus reactivation from the TO. Previous work from our group using
a thymidine kinase knock out (tk-I-) virus (virus unable to reactivate in TO)
demonstrated that viral antigens were undetectable in the corneal stroma and
lesions were minimal (94). This observation indicates that the source of virus
23

.. [

in the corneal stroma is from the TO, an interpretation further supported using
an Us9-/- mutant virus that retains normal peripheral virulence but fails to
transport anterograde after any reactivation (personal communication with Dr,
David Johnson, Oregon Health Centre). We observed that irrespective of the
dose used, Us9-/- virus failed to arrive in the corneal stroma and the mice had
diminished, although not absent SK lesions (our unpublished data). These
results support a mechanistic role for stromal virus in the bystander model but
do not reveal how such virus contributes to the inflammatory effect. We are
currently evaluating the role of a number of candidate mechanisms. These
include the PAMP effect, superantigen expression and inflammatory reactions
driven by stress proteins
In immunocompetent animals, it could be that HSV induces SK
indirectly in a "hit and run" fashion. Thus virus replication might only serve to
set off an inflammatory and angiogenic response that becomes sustained
without the further participation of virus. Should this be the case, then HSV
induced

immunopathological

lesion

differs

from

most

viral

immunopathologies since viral persistence is the normal circumstance. Our
view is that HSV replication is required to marshal a complex of events, which
we term the "alarm complex". This collage of molecules serves directly or
indirectly to signal the ingress and subsequent activation of neutrophils and
DCs in the stroma and angiogenic sprouting from the limbal blood vessels.
The PMN are activated to release more proangiogenic and angiogenic factors
that expand the vascular bed. Once sufficient in extent, these leaky vessels act
as conduits for T cells which now include the HSV specific T cells from
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lymph nodes. Meanwhile, viral antigens are taken up and processed by DCs
which present them to viral antigen specific CD4+ T cells. These respond by
releasing more inflammatory mediators which serve to recruit and activate
additional T cells, most of which are now not HSV specific and some of which
may be autoreactive. These recruits release more inflammatory molecules
(bystander activation) in a positive feedback loop that gradually ceases as
levels of activators fall and terminators increase (Fig 4B, 5). The stroma is left
with a damaged matrix and unwanted vascular bed that is slow to resolve.
Current studies are ongoing to verify this pathogenesis scheme of events.

CONCLUSION
In conclusion, the pathogenesis of SK, as revealed by animal studies, is
complex. Virus replication is necessary for the lesions but may not be directly
involved in driving the chronic immunopathology. Many early events caused
by virus have been identified and shown to form part of the process. The
mystery remains as to mechanistic events which account for the chronic
progressive lesion that impairs vision. One hopes that understanding this
process could reveal clues that may help control this unfortunate disease.

SPECIFIC AIMS AND RATIONALE
Studies with the mouse model for HSK have revealed the involvement of
complex cellular and molecular mechanisms in its pathogenesis. Several areas,
both in the clinical and pre-clinical phase, require further elucidation. These
include viral replication, the early proinflammatory events, innate and
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adaptive immune cell influx and neovasculariztion of the avascular cornea.
Understanding these early events is critical, since many of these early events
are subject to modulation providing an approach to controlling this important
cause of human blindness. Studies described here have been aimed at
understanding the above mechanisms further.
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Fig 1. Crucial events in HSK pathogenesis.
Following Herpes simplex virus type 1 (HSV -1) infection replicating virus is
detectable in the cornea till 5- 6 days p. i. Viral mRNA is detectable till 7- 8
days p. i. However viral DNA persists in the cornea till day 20 p. i.
Angiogenesis or new blood vessel development from existing limbal vessels
starts at 24 hr pj. and gradually peaks around day 15 p. i. The early cell influx
in the corneal stroma is dominated by polymorphonuclear leukocytes (PMN).
PMN influx is characterized by a typical biphasic response. This response
starts around 18 hr p. i., peaks at 48 hr p. i., declines around 5 days pj. and
then comes back during the clinical phase. Whereas the T cells enter the
cornea during the clinical phase around 8-9 days p. i.
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Fig 2. Schematic representation ofsome early events in HSK pathogenesis.
Herpes simplex virus type 1 (HSV -1) infection of the corneal epithelial cell
layer resulted in the production of plethora of proinflammtory cytokines and
chemokines early after infection. These cytokines and chemokines create an
inflammatory milieu that makes the corneal environment favorable for a
prompt inflammatory cell influx such as polymorphonuclear leukocyte
(PMN), macrophages and natural killer cells (NK cells). The set is also set for
subsequent events that continue into the clinical phase such as tissue
destruction by PMN (mainly neutrophil) and corneal neovascularization which
is mainly regulated by an interplay between angiogenic factors (VEGF, MMP
9) and antiangiogenic factors (IP-I0). Newly developed blood vessels in
corneal stroma in tum act as a conduit for inflammatory cell influx during the
clinical phase. Question mark (?) indicates identity of factors responsible for
paracrine IL-12 production is not known.
Abbreviations:

IL, Interleukin; IFN-y, Interferon gamma; VEGF, vascular

endothelial growth factor; COX-2, Cycloxygenase 2; PGE2, Prostaglandin
MIP-2, Macrophage Inflammatory protein 2; IP-I0, Interferon inducible
protein 10; MiG, Monokine induced by IFN-y; PECAM 1, Platelet endothelial
cell adhesion molecule 1; MHC II, Major Histocompatibility complex II;
MMP-9, Matrix metallo proteinase 9; PMN, Ploymorphonuclear leukocyte,
NK cells, Natural killer cells.
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Fig 3. The molecular mimicry model of SK pathogenesis
The figure summarizes the relative roles of molecular mimicry and
nonspecific inflammation in SK pathogenesis. This concept explains that the
virus replication and non specific immune responses some how unmasks
autoantigens in the eye and additionally stimulates an antiviral T cell
responses that is cross-reactive with the corneal autoantigens.
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Fig 4A and B. The Bystander activation model ofSK pathogenesis.
A summary of events initiated at the preclinical phase and ending in the
clinical phase of herpetic stromal keratitis is shown in both immunocompetent
and immunocompromised model. The inflammatory events set off by viral
replication continue into the clinical phase. In immunocompetent animals
these molecules play important role in ingress and subsequent activation of
neutrophils and DCs in the stroma and angiogenic sprouting from the limbal
blood vessels. These blood vessels act as conduits for T cells which now
include the HSV specific T cells from lymph nodes. Meanwhile, viral antigens
are taken up and processed by DCs which present them to viral antigen
specific CD4+ T cells. These respond by releasing more inflammatory
mediators which serve to recruit and activate additional T cells, most of which
are now not HSV specific and some of which may be autoreactive. However,
in immunocompromised animals inflammatory molecules produced as a
consequence of ocular HSV infection activate the T cells in a non TCR
mediated manner. In this instance, virus persisted and spread to the stromal
tissue location in some way. This continually replicating virus in the corneal
stroma acts, possibly by TLR ligand activity, as the chronic stimulus for
cytokine Ichemokine production that in tum activates the incoming T cells.
Such cells then produce inflammatory mediators which participate in tissue
damage.
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Fig 5. The Hit and Run model of SK pathogenesis.
HSV-1 replication is required to marshal a complex of molecular events,
which we term the "alarm complex". These molecules serves directly or
indirectly to signal the ingress and subsequent activation of innate immune
cells in the stroma and angiogenic sprouting from the limbal blood vessels.
The innate immune cells are activated to release more proangiogenic and
angiogenic factors that expand the vascular bed. Once sufficient in extent,
these leaky vessels act as conduits for adaptive immune cells (T cells) which
now include the HSV specific T cells from lymph node. These T cells in tum
produce more inflammatory mediators which serve to recruit and activate
additional T cells, most of which are now not HSV specific and some of which
may be autoreactive. These recruits release more inflammatory molecules
(bystander activation) in a positive feedback loop. The stroma is left with a
damaged matrix and unwanted vascular bed that is slow to resolve. The dotted
arrow and the question mark indicate that still no evidence is available about
the direct involvement of virus or viral components in the angiogenesis
process.
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PART II

MICE TRANSGENIC FOR IL-l RECEPTOR
ANTAGONIST PROTEIN ARE RESISTANT
TO HERPETIC STROMAL KERATITIS:
POSSIBLE ROLE FOR IL-l IN HERPETIC
STROMAL KERATITIS PATHOGENESIS
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Research described in this chapter is a slightly modified version of an article
published in 2004 in The Journal of Immunology by Partha Sarathi Biswas,
Kaustuv Banerjee, Bumseok Kim and Barry T. Rouse.

Biswas, P. S., K. Banerjee, B. Kim, and B. T. Rouse. 2004. Mice transgenic
for IL-l receptor antagonist protein are resistant to herpetic stromal keratitis:
possible role for IL-l in herpetic stromal keratitis pathogenesis. J. Immunol.

172: 3736. Copyright 2004. The American Association ofImmunologists, Inc.
In this chapter "we" and "our" refers to co-authors and me. My contributions
in the paper include (1) selection of the topic (2) data analysis and
interpretation (3) planning experiments (4) compiling and interpretation of the
literature (5) understanding how results fit with the literature (7) compilation
of contributions into one paper (8) providing structure to the paper (9) making
graphs, figures and tables (10) writing and editing.

ABSTRACT
Ocular infection with herpes simplex virus (HSV) may result in the blinding
immunoinflammatory lesion Stromal Keratitis (SK). Early events in the
pathogenesis that set the stage for SK are poorly understood. The present
report evaluates the role of IL-l using a transgenic mouse that overexpresses
the IL-l receptor antagonist protein. Such transgenic mice were markedly
resistant to SK compared to IL-l Ra -/- and C57BU6 control animals.
Targeting IL-l could prove to be a worthwhile therapeutic approach to control
SK,

an

important

cause
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of

human

blindness.

.

INTRODUCTION
Herpes simplex virus (HSV) infection is a major cause of vision loss (1). This
results mainly from a chronic inflammatory reaction in the normally
transparent and avascular cornea. A complex of humoral and cellular events
are involved in the pathogenesis of SK, but the critical event responsible for
clinically evident lesions is CD4+ T cell mediated immunopathology (2, 3).
Prior to the T cell mediated immunoinflammatory phase, multiple events
occur after virus infection that set the stage for the subsequent pathology.
These events include the production of proinflammatory cytokines and
chemokines and a prominent invasion of the cornea by PMN (4, 5). The later
response appears protective and helps clear virus (4, 5). However, PMN
invasion also contributes to pathology since the cells are a major source of
angiogenesis factors (6) and perhaps also damaging factors such as NO (7).
Neovascularization, represents a maj or step in SK pathogenesis and mUltiple
molecules are involved in this process (8). It is not clear how HSV infection,
which in the mouse model is usually confined to the corneal epithelium,
results in neovascularization into the underlying stroma. Thus once a cell is
productively infected by HSV most cellular proteins cease production (9).
Exceptions include IL-6 (10, 11) and probably IL-l (12) which are briefly
induced by HSV infection by mechanisms that remain undefined. These
cytokines could represent key molecules that set off a cascade of events that
culminate in the clinically evident immunoinflammatory lesions. After HSV
infection, both IL-l and IL-6 have been shown to be eminent by day 2 post
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infection and reached peak levels at day 10, and then diminished over the next
few days (13, 14). In consequence, counteracting IL-l and IL-6 could be a
valuable control measure at least if performed early after infection. The aim of
this study was to determine if inhibition of IL-l, as could be achieved by using
a transgenic mouse that overexpressed the IL-l receptor antagonist, had an
effect on SK pathogenesis. Such transgenic mice have been used in other
inflammatory models and were shown to block IL-l and diminish disease
expression (15-18). Our results with ocular infection with HSV demonstrate
that IL-l Ra Tg mice developed significantly milder disease and reduced
corneal angiogenesis compared to IL-l Ra -/- and C57BU6 mice. This
difference in disease phenotype was an indirect event and was shown to be the
consequence of changed expression of molecules such as IL-6, MIP-2 and the
angiogenesis factor VEGF normally unregulated by IL-l

during an

inflammatory process (19-21). Our results demonstrate that IL-l production is
a critical event in SK pathogenesis and that inhibiting this cytokine represents
a valuable approach for disease control.

MATERIALS AND METHODS
Mice
IL-l receptor antagonist transgenic (T14 hemizygous line) and knockout mice
were kindly provided by Dr. David Hirsh (Department of Biochemistry and
Molecular Biophysics, College of Physician and Surgeons, Columbia
University). Wild type female 4 to 5 weeks old C57BU6 mice were purchased
from Harlan Sprague-Dawley (Indianapolis, Indiana). Animals were sex and
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age

matched for

all experiments.

All manipulations

involving

the

immunocompromized mice were performed in a laminar flow hood. To
prevent bacterial superinfections, all mice received prophylactic treatment
with Sulphatrim pediatric suspension (Barre-National Baltimore, MD). All
experimental procedures were in complete agreement with the Association for
Research in Vision and Ophthalmology (ARVO) resolution on th,e use of
animals in research.

Virus

HSV-l RE (obtained from Dr. Robert Hendricks Laboratory, University of
Pittsburgh School of Medicine) was used in the present study. The virus was
propagated and titrated on monolayers of Vero cells (ATCC, Cat No. CCL81)
using standard protocols (22). Infected Vero cells were harvested, titrated and
0

stored in aliquots at _80 C until used.

Corneal HSV -1 infection

Corneal infections of all mice groups were conducted under deep anesthesia
induced by intraperitoneal injection of Avertin (Sigma). Mice were scarified
on their corneas with a 27-gauge needle and a 4J..lI drop containing the required
dose of virus was applied to the eye and gently massaged with the eyelids.
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Clinical observations and Angiogenesis Scoring
The eyes were examined on different days post infection by a slit-lamp
biomicroscope (Kowa Co. Nagoya, Japan), and the clinical severity of keratitis
of individually scored mice was recorded as described before (8).
Angiogenesis severity was measured as described previously (23). Briefly, a
grade of 4 for a given quadrant of the circle represents a centripetal growth of
1.5mm toward the corneal center. The score of the 4 quadrants of the eye were
then summed to derive the NV index (range 0-16) for each eye at a given
point.

In vitro stimulation of corneal epithelial cell culture
Isolation of corneal epithelium cells were performed as described before (24).
Briefly corneal buttons were incubated at

3i C in phosphate buffered saline

containing 10mM tetra sodium diaminetetracetate dehydrate (Sigma) for 45
minutes. After incubation, the epithelial cell layer. was separated from the
adjacent corneal tissue by gentle teasing with a fine forceps. The intact
epithelial layer was washed several times in PBS followed by treatment with
collagenase D (Roche) at 37° C for 30 minutes. The disrupted epithelial cells
were then passed through a 40Jlm filter to make a single cell suspension. Cells
were counted and suspended in F-12K medium (ATCC) with 10% FCS and
plated in 48 well tissue culture plates at

3i C in 5% C02. Purity of cultured

corneal epithelial cells was determined by flow cytometry using anti K12
antibody (kindly provided by Dr. Winston Kao, University of Cincinnati). The
corneal epithelial cell culture yielded 75-80% purity.
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Adherent monolayer of epithelial cells was stimulated with different
doses of recombinant murine IL-l a and IL-l ~ (R & D systems) in serum free
F-12 K medium for 24hr and 48hr. After incubation, the supernatant was
0

collected and stored at _80 C till further use. For blocking studies, different
doses of anti-murine IL-1a antibody (Pharmingen) was mixed with 800pg
(dose selected on the basis of dose response curve) of IL-1a. Rat IgG was
used as isotype control.

Corneal intrastromal injection assay
Corneal intrastromal injection was performed as described before ct).Under
direct stereomicroscopic .observation, a nick in the epithelium and anterior
0

stroma of mouse cornea was made with a Yl- inch 30-gauge needle with a 30
bevel in the mid periphery. Eight eyes were injected per group. The needle
was introduced into the corneal stroma and advanced 1.5 mm to the corneal
center. Two microlitres of solution containing the required concentration of
recombinant murine IL-1a (lOOng, 200ng and 400ng) (Pharmingen) and anti
murine VEGF antibody [5J.!g (25)](R & D system) was forcibly injected into
the stroma to separate the corneal lamellae and disperse the solution. PBS was
used as control.

Subconjunctival inoculations
Subconjunctival inoculation of recombinant murine IL-6 [50ng (26)]
(Pharmingen) and anti murine 1L-6 antibody [5J.!g/JlI (26)] was performed as
described previously (26). Briefly, subconjunctival inoculations were done
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using a 2 cm 32 gauge needle and syringe (Hamilton) to penetrate the
perivascular region of conjunctiva and deliver 4JlI into the subconjunctival
space. Control mice received PBS. Mice received recombinant murine IL-6 a
day before corneal infection with HSV -1 RE.

Viral titration
Eye swabs were taken from the infected corneas (3 mice/group) using sterile
cotton swabs soaked in DMEM containing 10 IU/ml penicillin and 100Jlg /ml
streptomycin. All manipulations are done under sterile conditions. Swabs were
0

stored in tubes containing serum free DMEM at _80 C. For detection of virus,
samples were thawed and vortexed. Duplicate samples (200JlI) were plated on
Vero cells grown to confluence in 24 well plates at 37°C in 5% C02 for 90
minutes. Medium was aspirated and 500JlI of DMEM containing 1% LMP
agarose was added to each well. Titers were calculated as 10glO pfu/ml as per
standard protocol (22).

Histopatbolgy
For histopathological analysis, eyes were extirpated and fixed in 10% buffered
neutral formalin. Staining was performed with Hematoxylin and Eosin
(Richard Allen Scientific, MI).

RT-PCR

Total RNA from 4 corneas per time point was extracted by using Tri-reagent
(Molecular Biology Inc., Cincinnati, Ohio). Total RNA (1 Jlg) was reverse
58

transcribed using murine leukemia virus reverse transcriptase (Gibco BRL
Life Technologies, Bethesda MD) with oligodT as primer (Invitrogen, CA).
All cDNA samples were aliquoted and stored at -20°C until further use.
Polymerase chain reaction was performed in PTC-1oo Programmable Thermal
Controller (MJ Research Inc.) using Hot Start PCR Master Mix (Promega,
WI).

The

primers

used

were

CATCCTGCACCACCAACTGCTTAG

murine

GAPDH

Forward
Reverse

GCCTGCTTCACCACCTTCTTGATG and murine IL-1 Ra Tg Forward
TAGACATGGTGCCTATTGAC Reverse GAGGCTCACAGGACGGTCAG.

Flow Cytometry
Single-cell suspensions -were prepared from 4 corneas at 24 and 48 hr post
infection as described elsewhere (27), with some modifications. Briefly,
corneal buttons were incubated with collagenase D (Roche) for 60 min at 37°C
in a humidified atmosphere at 5% CO 2 . After incubation, eyes were disrupted
by grinding with a syringe plunger and passing through a cell strainer. Cells
were washed and suspended in RPMI 1640 with 10% FBS. The Fc receptors on
the cells were blocked with unconjugated anti-CD16/32 (Pharmingen) for 30
min. Samples were incubated with FITC labeled anti Gr-1 antibody (Clone
RB6-8C5, Pharmingen) and isotype controls for 30 minutes. All samples were
collected on a FACScan (BD Biosciences), and data were analyzed using
CellQuest 3.1 software (BD Biosciences).
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Cytokine ELISA of corneal lysate
For preparation of corneal lysates, 6 corneas per time point were pooled and
minced. All procedures were done on an ice bath. Minced pieces were
collected in 1ml DMEM without FCS and homogenized using a tissue
homogenizer (PRO Scientific Inc., Mourse)

four times, 15 seconds each,

with a gap of 1 minute between homogenization to allow the sample to cool.
The lysate was then clarified by centrifugation at 14,000 rpm for 5 minute at
4°C. The supernatant was collected and used immediately or stored at _80°C
until further use. Lysates were analyzed using a standard sandwich ELISA
protocol. Anti IL-6 capture and biotinylated detection antibodies were from
Pharmingen (Clone MP5-20F3) and standard recombinant murine IL-6 was
from R&D Systems Inc, Minneapolis. Anti MIP-2 and anti VEGF 164 capture
and biotinylated detection antibodies and recombinant standards for murine
MIP-2 and murine VEGF 164 were from R&D Systems. The color reaction
was developed using ABTS (Sigma) and measured with an ELISA reader
(Spectramax 340, Molecular Devices) at 405nm. The detection limit was
2pg/ml. Quantification was performed with Spectramax ELISA reader
software version 1.2.

Quantitative real time PCR
Total RNA from 4 corneas per time point was extracted by using RNeasy
RNA extraction Kit (Qiagen, CA). Briefly, tissues were lysed in RLT buffer
and RNA was purified following manufacturer's instructions (Qiagen, CA).
DNAse treatment (Qiagen, CA) was done to remove any contaminating
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genomic DNA. To generate cDNA, 1Jlg total RNA was reverse transcribed
using murine leukemia virus reverse transcriptase (Gibco BRL Life
Technologies, Bethesda MD) with oligodT as primer (Invitrogen, CA),
according to manufacturer's instructions. All cDNA samples were aliquoted
and stored at -20°C until further use.
Real time PCR was performed using a DNA Engine Opticon (MJ
Research Inc.).

PCR was performed using SYBR Green I reagent (Qiagen,

CA) according to manufacturer's protocol. PCR amplification of house
keeping gene, murine glyceraldehyde 3-phosphate dehydrogenase was done
for each sample as a control for sample loading and to allow normalization
between samples. A standard curve was constructed with PCR-II topo cloning
vector (Invitrogen, CA) containing the inserted same fragment amplified by
the SYBR I system. PCR reactions for each sample was analyzed in three
dilutions in duplicate for both GAPDH and target gene. The target gene was
then normalized to 106 copies of GAPDH control and data represented as copy
numbersll 06GAPDH. The primers used were murine GAPDH Forward
Reverse

CATCCTGCACCACCAACTGCTTAG
GCCTGCTTCACCACCTTCTTGATG

and

murine

VEGFR-2

TGTCAAGTGGCGGTAAAGG

Forward
Reverse

CACAAAGCTAAAATACTGAGGACTTG.

Statistical analysis
A standard student's t test was employed for statistical analysis.
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RESULTS
IL-l Ra Tg mice show reduced Stromal Keratitis and corneal
angiogenesis
Three groups of genetically different mice, IL-l Ra Tg, IL-l Ra -/- and wild
type C57BU6, were evaluated clinically for the development of SK following
HSV-l (5xl06 pfu) corneal infection over a 20 day test period. NaIve and
infected corneas of IL-l Ra Tg mice demonstrated higher level of IL-l Ra
mRNA in comparison to wild type control (Fig. 1). As shown in Fig. 2A,
whereas the pattern and severity of SK in both IL-l Ra -/- and wild type

C57BU6 mice was similar (mean scores 3.5 and 2.7 respectively), SK in IL-l
Ra Tg mice was strikingly reduced (mean score of 1.4) (Fig. 2A). In addition
whilst 75% of eyes of IL-l Ra -/- mice developed clinically evident lesions
(score 3 or greater), only 25% of IL-l Ra Tg mice developed such lesions
(data not shown). Attempts to infect IL-l Ra Tg mice with a higher virus dose
(107 pfu) resulted in lethality, but still few developed SK of ~ 3 (data not
shown). Histopathological analysis of representative eyes of IL-l Ra Tg mice
revealed mild inflammatory changes and cellular infiltrations in the corneal
stroma and epithelium at day 20 p. i. (Fig. 2B). However both IL-l Ra -/- and

C57BU6 mice developed more severe inflammatory changes (Fig. 2B).
One characteristic of corneal HSV -1 infection is neovascularization
into the normally avascular corneal stroma, an event deemed necessary for the
full expression of SK (28). In comparison to the extent of angiogenesis
following HSV infection in IL-l Ra -/- and C57BU6, the eyes of IL-l Ra Tg
mice revealed marked reduction of this process (Fig 3A, 3C). By day 20 p. i,
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the angiogenesis score was greater than lOin 13 of 16 IL-1 Ra -/- eyes and 8
of 16 C57Bl16 mice (Fig 3B) but only 4 out of 16 eyes of IL-1 Ra Tg mice
had such a score (Fig 3B). Taken together these results indicate that
overexpression of IL-1 Ra protein led to diminished angiogenesis as well as
stromal keratitis.

PMN inflammatory response in IL-l Ra Tg mice:

A major event following ocular infection with HSV is a prompt PMN influx
into the corneal stroma (4, 5). This reaction at 24 and 48 hr p. i. was
significantly less in IL-1 Ra Tg mice compared to either IL-1 Ra -/- and wild
type mice (Fig. 4, Table 1). PMN are considered as involved in antiviral
defense (4, 5). In line with this notion viral clearance was impaired in IL-1 Ra
Tg mice compared to IL-l Ra -/- and wild type mice (Table 2). Accordingly
virus was present in ocular swabs for around 2 extra days in IL-1 Ra Tg mice
(Table 2).
One reason considered for the scant PMN response in IL-l Ra Tg mice
was that IL-1, must, in nonnal situations serves to induce molecules that are
directly or indirectly chemotactic for PMN. Based on the results of others (26,
29) prime candidates considered were IL-6 and MIP-2. Levels of these
proteins were compared in the 3 mouse strains at various time points after
HSV infection. Both IL-6 and MIP-2 protein levels in corneal extracts were
significantly less in IL-l Ra Tg mice compared to IL-1 Ra -/- and wild type
animals at all time points analyzed (Fig. 5A & 5B). In addition, if recombinant
murine IL-6 protein was injected subconjunctivally into IL-1 Ra Tg animals 1
63

'"

day prior to corneal infection, there was an approximately 4 fold increase in
PMN influx in HSV infected IL-I Ra Tg mice compared to controls given
PBS (Fig. 6A, Table 3). Such eyes demonstrated a higher IL-6 level in
comparison to PBS control at day 2 post injection (data not shown).
Furthermore, IL-6 reconstitution also resulted in significantly higher levels
(p<O.05) of the chemokine MIP-2 in corneal extracts (Fig. 6B).

To evaluate which corneal cells might act as a source of IL-6 upon IL
l stimulation, corneal epithelial cell cultures were stimulated in vitro with

different doses of recornbinant IL-Ia and
l~,

IL-I~.

Interleukin-Ia, but not IL

could induce IL-6 production from corneal epithelial cells in a dose

dependent 111allner at 24 hr and 48 hr (Fig. 7A). The presence of neutralizing
antibody against murine IL-Ia, but not control IgG, blocked the IL-6
production from these cells in a dose dependent manner (Fig. 7B).

Environment favorable for corneal angiogenesis is severely compromised
in IL-l Ra Tg mice
As noted above, IL-I Ra Tg mice developed markedly diminished angiogenic
responses compared to either IL-I Ra -/- and wild type controls. Protein levels
of VEGF was significantly lower (p<O.05) in IL-I Ra Tg mice compared to
IL-I Ra -/- and C57BL/6 animals at all time points analyzed (Fig. 8A). In
addition, real time PCR demonstrated a significantly higher level of VEGFR-2
mRNA transcript in IL-I Ra -/- and C57BU6 mice than in IL-I Ra Tg animals
(Fig.8B).
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Previous studies demonstrated that IL-I a could upregulate the
angiogenesis factor VEGF in human PBMC in vitro (20). To demonstrate the
angiogenic activity of IL-Ia in murine cornea, different doses of recombinant
murine IL-I a was injected intrastromally and the extent of angiogenesis was
measured at day 2 and 4 days postinjection. Corneal ELISA revealed a
significant increase in IL-I a level at day 2 post injection in comparison to
PBS control (data not shown). Interestingly, IL-Ia induced a dose dependent
angiogenic response (Fig. 9A, 9B). In such eyes, both IL-6 and VEGF protein
levels were elevated (Fig. lOA, lOB). Administration of neutralizing antibody
against

murine

VEGF

could

abrogate

IL-I a

induced

angiogenesis

demonstrating the key involvement of VEGF in this process (Fig. IIA). Such
eyes demonstrated diminished VEGF level in comparison to IgG control (data
not shown). In order to rule out the possible involvement of IL-6 in the IL-I a
mediated corneal angiogenesis, anti IL-6 antibody was administered with IL
Ia protein. Interestingly the presence of neutralizing antibody against IL-6
reduced, but did not abrogate IL-Ia induced corneal angiogenesis (Fig. lIB).

DISCUSSION
This report deals with early events in the pathogenesis of the blinding
immunoinflammatory lesion Stromal Keratitis caused by ocular infection with
HSV. Our results demonstrate that transgenic mice that overexpress the IL-I
receptor antagonist protein are markedly resistant to SK compared to control

C57BU6 mice. The resistance appeared to be the consequence of a reduced
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expression of molecules usually induced by IL-l, which in tum participate in
inflammatory cell recruitment and angiogenesis. In the present report, we
evaluate the critical role of IL-l using a transgenic mouse that overexpress IL
l receptor antagonist protein. Thus IL-l Ra Tg mice had reduced levels IL-6,
the chemokine MIP-2; as well the angiogenesis factor VEGF and its receptor
VEGFR-2. In consequence, the IL-l Ra Tg mice showed less PMN influx and
neovascularization than did control C57BU6 animals. Our results imply that
blocking IL-l activity could represent a valuable therapeutic approach to
control SK.
One striking difference noted between C57BU6 control and IL-l Ra Tg
mice was a marked difference in PMN invasion 2 days post HSV infection.
This early PMN response was shown previously to be in part responsible for
viral clearance (4, 5). This viewpoint was also supported by the present
studies. Thus, IL-l Ra Tg mice, which expressed a diminished PMN response,
also showed a delay in viral clearance. How IL-l in normal infected mice
causes PMN influx remains unclear. However, since IL-l itself is not
chemotactic for PMN (30), the effect must be indirect, with IL-l inducing one
or more chemokines. A likely candidate is MIP-2, since MIP-2 neutralized
mice develop minimal PMN responses to ocular HSV infection (29). The
results of the present study indicate that IL-l did induce MIP-2 but this was an
indirect consequence of IL-6 induction. In support, IL-l a was shown to
induce IL-6 in vitro in corneal epithelial cells. In addition, MIP-2, as well as
other chemokines, such as MIP-l a and MCP-l, were shown by others to be
induced by IL-6 (26, 31). Our studies also demonstrated that IL-l was
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upregulated in virus infected corneal epithelial cells (data not shown). This
observation as well as others (10-12) indicates that HSV infection results in
the autocrine production of IL-l as well as IL-6. This process may be brief
since as HSV infection proceeds, host mRNA synthesis and protein translation
is inhibited in productively infected cells (9). However, IL-l also drives IL-6
production by uninfected cells, which together with that produced by infected
cells themselves, sets off a cascade of events that result in PMN influx.
Supporting the scheme we could show that the provision of exogenous IL-6
intrastromally to the transgenic mice, reconstituted the PMN invasion.
Although PMN playa protective function in HSV ocular infection, they
also participate in lesion expression and act as a source of angiogenesis factors
(6) as well as molecules such as nitric oxide (7) that damage corneal tissues.
Thus, in line with the minimal early PMN response noted in IL-l Ra Tg mice,
such animals showed a marked reduction in angiogenesis compared to
controls. One factor derived from PMN, as well as from other cell types
involved in neovascularization, is VEGF (32, 33). We demonstrated that
VEGF was significantly downregulated in IL-1 Ra Tg mice in comparison to
control animals. Similar observations were reported previously in a
nonspecific model of ocular inflammation (34). The diminished VEGF
response of transgenic mice may be explained by the fact that the presence of
the IL-l receptor antagonist suppressed IL-l induced VEGF production from
uninfected corneal cells such as PMN. Previously, HSV infection was shown
to cause VEGF production but not from the cells actually infected with virus
(8). Conceivably, cytokines such as IL-l released from infected cells explain
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the paracrine induction of VEGF. Supporting this scheme, the presence of IL
l Ra suppressed the VEGF response. In addition, the angiogenic response
induced in mice by intrastromal injection of IL-l could be largely inhibited by
anti VEGF antibody. Furthermore, intrastromal injection of IL-la was shown
to induce VEGF in the cornea. These observations as well as others in tumor
systems (20, 35) indicate that IL-l can cause cells to produce VEGF.
Even though IL-l produced from HSV infected cells may act as an inducer
for VEGF production, an additional VEGF stimulant appeared to be mediated
by the cytokine IL-6. Thus we demonstrated that corneal cells exposed to IL-l
in vitro produce IL-6, and IL-6 was shown previously to be a strong agonist
for VEGF production «36, 37). Further support that IL-l

induced

angiogenesis depended in part on IL-6 production was the observation that it
was partially blocked by anti IL-6 antibody. The relative importance of the
direct and indirect effect of IL-l on VEGF production and angiogenesis
remains to be evaluated.
Finally, our results demonstrated that corneal RNA samples from
transgenic mice showed diminished VEGFR-2 levels measured by Real Time
peR. In tumor systems, IL-l was shown to upregulate VEGFR-2 expression
on endothelial cells (38), the latter known to be critical for pathological
angiogenesis (39). Evidently, the absence of IL-l activity, as occurred in IL-l
Ra Tg mice, results in reduced expression of VEGFR-2. The consequence is
lack of stimulation for the endothelial cells to proliferate, resulting in reduced
angiogenesis. However it is not clear why transgenic mice demonstrated
reduced VEGFR-2 expression. We believe there may be two possibilities.
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Firstly, IL-l may directly upregulate VEGFR-2 expression on corneal
endothelial cells and blocking its activity by specific antagonist protein results
reduced receptor expression. Secondly, reduced proliferation of endothelial
cells as a consequence of diminished VEGF and inflammatory response in
these mice. Weare currently attempting to ascertain which of these two
mechanisms accounts for the major effect of IL-l on angiogenesis.
Taken together, our results support the hypothesis that the inflammatory
milieu and angiogenic stimuli created early after infection play an important
role in HSV induced ocular lesions. An important participant of this
environment is IL-l. Antagonizing the effect of IL-l by a specific receptor
antagonist protein abrog3:tes the cascade of events that culminate in HSK. This
regulation is indirectly mediated by downregulating various signaling
molecules previously known to be hnportant in HSK pathogenesis and corneal
angiogenesis. It would seem that targeting IL-l could prove to be a
worthwhile therapeutic approach to control SK, an important cause of human
blindness.
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Fig 1. Expression of corneal IL-l Ra mRNA at various time points after
HSV infection
At different time points p. i., corneas (n = 4) were isolated and total RNA was
extracted using Tri-Reagent. Total RNA (lJlg) was converted into cDNA as
described in the materials and methods. Polymerase chain reaction was
performed in PTC-100 Programmable Thermal Controller, M J Research
Incorporation. Murine GAPDH served as internal control. Lane M- Molecular
weight marker; Lane 1- C57BU6 naIve; Lane 2- C57BU6 day 2 p. i.; Lane 3

C57BU6 day 5 p. i.; Lane 4- IL-1 Ra Tg naIve; Lane 5- IL-1 Ra Tg day 2 p. i.;
Lane 6- IL-1 Ra Tg day 5 p. i.

78

A

B

S

e

4

Q

~

c:'-l

"3
-a

3

:

2

6

~

~

...
••••
•••••
(1 . 4)

1
0

--

... I ••

ttttt ••••
(3 . 5)

ttttt •••
---rT"n'

ftt·

•••
••

IL-1- Ra. T K I L -l. Ra. -1- CS7BL/6

Fig 2. Reduced HSK severity in IL-J Ra Tg mice
A. Mean lesion HSK score at day 20 p. i. of mice infected with 5x106 pfu
HSV-1 RE. Each dot represents the HSK score from one eye. Horizontal bars
and figures in the parenthesis indicate the mean for each group. Data is
compiled from two separate experiments consisting of 8 eyes in each group.
B. Mice were infected with 5x106 pfu HSV-1 RE. Mice were terminated at day
20 p. i. and eyes were processed for paraffin embedding. Hematoxylin and
Eosin staining was carried out on 6Jl sections. Magnification x 200.
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Fig 3. IL-l Ra Tg mice show reduced angiogenic response following HSV-l
infection at day 20 p. i.
A. Kinetics of corneal neovascularization process in mice infected with 5xI06
pfu HSV -1 RE. Angiogenesis scores were recorded as mentioned in the
Materials and Methods at indicated time points. Data is compiled from two
separate experiments involving 8 eyes per group and is expressed as Mean ±
SD. *Statistically significant differences in angiogenesis score (p< 0.05) were
observed between IL-I Ra Tg mice to either IL-I Ra KlO and C57BU6 mice.
B. Angiogenesis scores for individual eyes of IL-I Ra Tg, IL-iRa -1- and
6

C57BU6 mice infected with 5xI0 pfu HSV-I RE at day 20 p. i. Horizontal

bars and figures show the mean for each group. Data are compiled from two
separate experiments consisting of 8 eyes per group. *Statistically significant
differences in angiogenesis score (p< 0.05) were observed between IL-I Ra Tg
mice to either IL-I Ra KlO and C57BU6 mice.
C. At day 20 p. i. extensive growth of blood vessels can be seen in IL-I Ra -l
and C57BU6 mice infected with 5xI06 pfu HSV-I RE. IL-I Ra Tg mice show
minimum angiogenic sprouts near the limbal ring with the same dose.
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Fig 4. Presence of abundant Gr-I +ve cells in the cornea of [L-I Ra -/- and
C57BU6 mice but not in [L-I Ra Tg mice at 48 hr p. i.
Single cell suspensions of corneal cells were prepared from 4 eyes at 24 and
48 hr p. i. The cells were counted and stained with FITC labeled anti Gr-l
antibody and numbers of Gr-l positive cells were enumerated by FACS.
Histogram is representative of one of three separate experiments. Shaded and
open histogram represents Gr-l +ve cells at day 2 p. i. from uninfected and
infected corneas respectively.
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Fig 5. Reduced IL-6 and MIP-2 protein levels in HSV-l infected corneas of
IL-l Ra Tg mice.

A & B. At indicated time points, 6 corneas / group were processed for
measuring the IL-6 and MIP-2 protein levels. Levels of IL-6 and MIP-2 was
estimated from supernatants of corneallysates of mice infected with 5x106 pfu
HSV-1 RE by an antibody capture ELISA as outlined in materials and
methods. Results are expressed as Mean ± SD of three separate experiments (6
corneas/time point). *Statistically significant differences in IL-6 and MIP-2
level (p< 0.05) were observed between IL-1 ra Tg mice to either IL-I Ra KlO
and C57BU6 mice at all time points analyzed.
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Fig 6. Increased Gr-l+ve cells and MIP-2 levels in recombinant murine IL
6 reconstituted I L-l Ra Tg corneas at 48 hr p. i.
A. Mice transgenic for IL-I Ra protein received recombinant murine IL-6
(50ng) subconjunctivally 24 hr before corneal HSV -1 infection. PBS was used
as negative control. Single cell suspensions of corneal cells were prepared
from 4 eyes at 24 and 48 hr p. i. The cells were counted and stained with FITC
labeled anti Gr-I antibody and numbers of Gr-I positive cells were
enumerated by FACS. Histogram is representative of one of three separate
experiments. Shaded and open histogram represents Gr-I +ve cells at day 2 p.
i. from PBS and IL-6 reconstituted corneas of IL-I Ra Tg mice respectively.
B. At 48 hr p. i., 6 corneas each from IL-6 reconstituted and PBS control
group were processed to measure the MIP-2 protein levels. Levels of MIP-2
was estimated from supernatants of corneal lysates of mice infected with
5xI06 pfu HSV-1 RE by an antibody capture ELISA as outlined in materials
and methods. Results are expressed as Mean

±

SD of three separate

experiments (6 corneas/time point). *Significant difference (p<O.05) compared
to PBS treatment.
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Fig 7. fL-I «induced fL-6 production/rom corneal epithelial cells.
A. Corneal epithelial cells were stimulated with different doses of recombinant
murine IL-l a for 24 and 48 hr. Supernatants were collected and levels of IL-6
production was measured by an antibody capture ELISA as outlined in
materials and methods. Results are expressed as mean ± SD of three separate
experiments. *Significant difference (p< 0.05) compared to media control.
B. Corneal epithelial cells were stimulated with 800pg of recombinant murine
IL-l a along with different doses of anti IL-l a antibody for 24 hr.
Supernatants were collected and levels of IL-6 production was estimated by an
antibody capture ELISA as outlined in materials and methods. Results are
expressed as mean

± SD of three separate experiments (6 corneas/time point).

*Significant difference (p< 0.05) compared to rat IgG control.
** Significant difference (p< 0.05) compared to media control.
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Fig 8. Reduced VEGF protein levels and diminished expression of VEGFR..
2 mRNA expression in HSV..I RE infected corneas ofIL- IRa Tg mice
A. At indicated time points 6 corneas /group were processed to measure the
VEGF protein levels. Levels of VEGF was estimated from supernatants of
corneal lysates of mice infected with 5xI06 pfu HSV -1 RE by an antibody
capture ELISA as outlined in materials and methods. Results are expressed as
mean

± SD of three separate experiments (6 corneas/time point). *Statistically

significant differences in VEGF level (p< 0.05) were observed between IL-l
Ra Tg mice to either IL-I Ra KlO and C57BU6 mice.
B. At 2, 5and 7 day postinfection 4 corneas/group were processed for the
extraction of cellular mRNA. Real time PCR analysis was conducted to detect
the VEGFR-2 mRNA expression in corneas of mice infected with 5xl06 pfu of
HSV-1 as described in materials and methods. Results are shown as mean

±

SD of three separate experiments. *Statistically significant differences
(p<0.05) were noted in the expression of VEGFR-2 between IL-iRa Tg to IL
1 Ra KlO and C57BU6 mice at 5 and 7 day p. i. aCopy number of the target
gene was normalized to 106 copies of GAPDH.
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Fig 9. IL-l a induces angiogenesis in a corneal intrastromal injection assay
A. Different concentrations of recombinant IL-l a (100ng, 200ng and 40Ong)
was injected intrastromally into C57BU6 corneas (n=8) and angiogenesis
scoring was carried out on days 2 and 4 post injection. VEGF (200ng) was
used as a positive control and PBS as negative control. Results expressed as
mean ± SD. *Significant difference (p<0.05) compared to PBS treatment.
B. Representative photographs of eyes at day 2 post injection with 200ng IL
l a showing finer blood vessel development than that seen with the same dose
of VEGF (white arrows). The PBS control showing no blood vessel
development. Black arrows indicate the site of intrastromal injection.
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Fig 10. IL-l ainduces IL-6 and VEGF production in the cornea
A&B. Corneas of C57BL/6 mice were injected intrastromally with 200ng of
recombinant murine IL-I a. Corneas were excised from mice after 48hr and
processed for detection of IL-6 and VEGF from corneal lysates as described in
materials and methods. Results are expressed as mean ± SD for three separate
experiments involving 6 corneas. *Significant difference (p<O.05) compared to
PBS treatment.
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Figl1. Neutralizing antibody against VEGF but not IL-6 can abrogate IL
l ainduced angiogenesis in the cornea.
A. Corneas (n=8) of C57BU6 mice were injected intrastromally with 200ng of
recombinant murine IL-I a alone, 200ng of recombinant murine IL-I a and
anti murine VEGF (5J.!g) antibody, anti murine VEGF (5J.!g) antibody only and
PBS. Angiogenesis scoring was carried out on days 2 and 4 post injection.
Results expressed as mean ± SD for three separate experiments. *Significant
difference (p<O.05) compared to mice treated with IL-I a alone (200ng).
**Significant difference (p<O.05) compared to mice treated with PBS.
B. Corneas (n=8) of C57BU6 mice were injected intrastromally with 200ng of
recombinant murine IL-I a alone, 200ng of recombinant murine IL-I a and
anti murine IL-6 (5J.!g) antibody, anti murine IL-6 (5J.!g) antibody only and
PBS. Angiogenesis scoring was carried out on days 2 and 4 post injection.
Results expressed as mean ± SD for three separate experiments. *Significant
difference (p<O.05) compared to mice treated with anti IL-6 antibody with IL

Ia. ··Significant difference (p<O.05) compared to mice treated with only anti
IL-6 antibody or PBS control.
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PART III

INVOL VEMENT OF IL-6 IN THE
PARACRINE PRODUCTION OF VEGF IN
OCULAR HSV-l INFECTION
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Research described in this chapter is a slightly modified version of an article
submitted for publication in the Experimental Eye Research published by
Partha Sarathi Biswas, Kaustuv Banerjee, Paul R. Kinchington and Barry T.
Rouse.

In this chapter "we" and "our" refers to co-authors and me. My contributions
in the paper include (1) selection of the topic (2) data analysis and
interpretation (3) planning experiments (4) compiling and interpretation of the
literature (5) understanding how results fit with the literature (7) compilation
of contributions into one paper (8) providing structure to the paper (9) making
graphs, figures and tables (10) writing and editing.

ABSTRACT
Following ocular HSV -1 infection neovascularization of the avascular cornea
is a critical event in the pathogenesis of herpetic stromal keratitis. Previous
reports indicate an essential role for proinflammatory cytokines in HSV
induced

angiogenesis.

This

present

study

evaluates

the

role

of

proinflammatory cytokines such as IL-6 in corneal angiogenesis following
virus infection. Our in vivo and in vitro data indicate that IL-6 produced from
virus infected cells can stimulate noninfected resident corneal cells and other
inflammatory cells in a paracrine manner to secrete VEGF, a potent
angiogenic factor. Antibody neutralization of IL-6 results in a significant
decrease in the number of VEGF producing cells in the cornea. Thus our result
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serve to further demonstrate the close relationship between proinflammatory
cytokines and VEGF induced corneal neovascularization.

INTRODUCTION
Ocular Herpes simplex virus 1 (HSV -1) infection may result in a chronic
iInmunoinflammatory lesion in the corneal stroma termed herpetic stromal
keratitis (HSK). In the murine model of HSV-locular infection, the
pathogenesis of stromal keratitis involves a CD4+ T cell mediated destruction
of the cornea (1). However, prior to the immunoinflammatory phase, multiple
events occur after virus infection that set the stage for the subsequent corneal
pathology. These events .include the production of proinflammatory cytokines,
chemokines and neovascularization of the normally avascular cornea (2, 3).
Angiogenesis occurs and new blood vessels sprout from limbal vessels within
24 h of HSV infection that eventually extend to the central cornea within 10
15 days (3). Such angiogenesis impairs vision and appears necessary for the
ingress of T cells responsible for orchestrating HSK and impairs vision (1).
Thus, neovascularization represents a major step in HSK pathogenesis, and
multiple molecules are involved in this process. One of these is vascular
endothelial growth factor (VEGF) (4). However, it is not known how HSV
infections, which in the mouse model are usually confined to the corneal
epithelium, results in VEGF production and initiate the angiogenesis process
in the underlying corneal stroma. Previous studies from our group
demonstrated that, 24 hr p. i. uninfected corneal resident cells are the principal
source of VEGF, indicating a possible paracrine effect. One hypothesis is that
97

molecules released from infected cells could stimulate other cell types to
produce VEGF. After HSV infection, both IL-1 and IL-6 are abundant by day
1 post infection (5, 6). These reach peak levels at day 10, and then diminish
over the next few days (5, 6). Interleukin-1 produced from HSV -infected cells
has been shown to be a potent VEGF inducer from uninfected resident corneal
cells (7).
In addition to IL-1 produced from HSV -infected cells which acts to
induce VEGF production, the aim of this study was to determine whether
cytokine IL-6 could act as an additional VEGF stimulant. Both in vitro and in
vivo observations demonstrate that IL-6 can stimulate uninfected corneal
epithelial cells and stromal fibroblast cell line to produce VEGF. In addition,
inflammatory cells, a critical component of murine HSK, can also be
stimulated to produce VEGF by IL-6. Taken together these results indicate
that production of VEGF following HSV infection is a paracrine event with
IL-6 produced from virus infected cells acting as one of the factors. Thus IL-6
cause uninfected resident cells and inflammatory cells to produce VEGF
which in tum led to corneal angiogenesis.

MATERIALS AND METHODS
Mice
Wild-type female 6-8 weeks old Balb/c mice were purchased from Harlan
Sprague Dawley (Indianapolis, IN). Animals were sex and age matched for all
experiments. All experimental procedures were in complete agreement with
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the Association for Research in Vision and Ophthalmology resolution on the
use of animals in research.

Virus
The virus HSV -1 RE-gC-EGFP is a gC-null derivative of the virus strain
HSV-1 RE (8) that expresses the EGFP gene under the control of the gC
promoter at the gC locus. To construct this virus, a plasmid was
derived in which the EGFP gene (obtained as an NheI-XbaI DNA fragment by
restriction enzyme digestion of the commercial plasmid pEGFP-N1:
Clontech Corp, Palo Alto, CA) was cloned directly into a unique NheI
site in the plasmid pUC8-gC. The latter plasmid is a cloned 949 base
pair PstI-EcoRI fragment (co-ordinated 95,811 to 96,789, given with
respect to the HSV -1 genome sequence) containing the promoter of gC and
the first part of the gC open reading frame, all in the vector pUC8.
The final resulting construct contains EGFP flanked by gC sequences,
with the EGFP gene under control of the gC promoter and fused in the
correct reading frame with the first 6 amino acids of gC. In this
plasmid, the EGFP gene is followed by part of the gC open reading frame.
The flanking gC sequences thus enable genetic recombination of the EGFP
into the gC locus of the HSV-1 genome. To derive recombinant virus,
the plasmid was linearized and cotransfected with purified HSV-1 RE DNA
into

vero cells

using the calcium phosphate precipitation method.

Following four days of incubation at 37°C, progeny virus in which
recombination had occurred was identified by screening plaques for
99

r

fluorescence under UV illumination. Fluorescent virus was then plaque
purified to homogeneity, and grown to stocks. The correct insertion of
the EGFP gene and the absence of wild type virus in the final stocks
were determined by Southern blot analyses. The virus was propagated and
titrated on monolayer of Vero cells (American Type Culture Collection,
Manassas, VA; catalogue CCL81) using standard protocols (9). Infected Vero
cells were harvested, titrated, and stored in aliquots at -80°C until used.

Cells and Cell lines:
Corneal epithelial cells were isolated fronl the cornea of Balb/c mice as
described with some modifications (10). Briefly, whole eyes were incubated at
37°C in PBS containing 10 mM tetra sodium diaminetetracetate dehydrate
(Sigma-Aldrich, St. Louis, MO) for 45 min. After incubation, the epithelial
cell layer was separated from the adjacent corneal tissue by gentle teasing with
a fine forceps. The intact epithelial layer was washed several times in PBS,
followed by treatment with collagenase D (Roche, Basel, Switzerland) at 37°C
for 30 min. The disrupted epithelial cells were then passed through a 40-JLm
filter to make a single cell suspension. In some cases, the intact epithelial cell
layer was used for the experiments.
The cell lines used for the experiments were MKT-1 (Murine Stromal
Fibroblast cell line) (kindly gifted by Dr Winston Kao, Department of
Ophthalmology,

University

of Cincinnati,

Cincinnati,

OH),

J774A.1

(Macrophage cell line ) (ATCC, Cat# TIB-67). The DC 2.4 (Dendritic cell line )
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was generously provided by Dr. K. L. Rock (Deptt. of Pathology, University
of Massachusettes Medical Schools, MA).

Corneal HSV -1 infection

Corneal infections of all mice groups were conducted under deep anesthesia
induced by i.p. injection of avertin (Sigma-Aldrich, St. Louis, MO). Mice were
scarified on their corneas with a 27 -gauge needle, and a 4 J!.l drop containing
5xl05 pfu of virus was applied to the eye and gently massaged with the
eyelids.

Subconjunctival injection

Subconjunctival inoculation of murine rIL-6 (BD PharMingen, San-Diego,
CA) and anti-murine IL-6 Ab (5 J!.g/J!.l) (BD Pharmingen, Rat IgG (5J!.g/J!.I)
(R& D Systems) and LPS (1J..tg/ml dissolved in PBS) (Sigma) was performed,
as described previously (11). Briefly, subconjunctivalinoculations were done
using a 2-cm 32-gauge needle and syringe (Hamilton, Reno, NV) to penetrate
the perivascular region of conjunctiva and deliver into the subconjunctival
space. Control mice received PBS only.

In vitro stimulation of corneal epithelial cell layer and cell lines with IL-6

For corneal epithelial cells, an intact corneal epithelial cell sheet was
incubated in DMEM without sera containing various concentrations of
recombinant IL-6 at 37 0 C and 5% C02 on a rotator shaker for 24 hrs. After 24
hrs, the cell sheets were spun down and total RNA was extracted. Treatment
101

with LPS (l j.lglml) (Sigma) and DMEM only was used as positive and
negative control.
For various cell lines (MKT-l, J774A.l and DC 2.4), 105 cells/well
were grown for 48 hrs in 6 well plate containing 10% FCS-DMEM. After 48
hrs of growth the cells were finally washed and stimulated with various
concentrations of recombinant IL-6 in serum-free DMEM for 24 hrs.
Following stimulation, the supernatants were collected and stored in -80 0 C
until used. Treatment with DMEM only was used as negative control and LPS
(l Jlglml) (Sigma) was used as a positive control.

Immunofluorescence staining and confocal microscopy
For immunofluorescence staining, eyes were enucleated at 24 hr. p. i. and snap
frozen in OCT compound (Sakura, Torrance CA). Six-micron-thick sections
were cut, air dried, and fixed in 4% para-formaldehyde at room temperature
for 20 min. Sections were blocked with 3% BSA-PBS containing 0.05%
Tween 20 and 1:200 dilution of Fc block (clone 2.4G2; BD PharMingen). Anti
VEGF biotinylated antibody (R&D systems, Minneapolis, MN) was diluted
(1: 100) in 1% BSA-PBS containg 0.1 % Triton-X and incubated overnight at

4°C. Sections were then treated with Streptavidin APC (BD Pharmingen) for
45 min. Corneal sections were repeatedly washed in PBS and mounted with
Vectashield mounting medium for fluorescence (Vector Laboratories Inc.
Burlingame, CA) and visualized with a confocal microscope (Leica, Wetzlar,
Germany).
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For immunofluorescence staining of IL-6 stimulated J774A.1, the
protocol was same except, fixation was done with Acetone-methanol (1: 1) at 
20° C and Streptavidin Alexa-fluor (Molecular Probes, Eugene, OR) was used
in place of Strepatividin APC. Following staining the J774A.1 cells was spun
down on microscopic slides using a cytospin machine. Slides were mounted
with Vectashield mounting medium for fluorescence (Vector Laboratories Inc.
Burlingame, CA) and visualized with a confocal microscope (Leica, Wetzlar,
Germany)

RT-PCR

To detect the presence of IL-6 receptors (gp80 and gp 130) on various cell
types, total RNA from corneal epithelial cell sheet, MKT-1, J774A.1 and
DC2.4 cells was extracted using RNeasy RNA extraction kit (Qiagen,
Valencia, CA). Briefly, tissues were lysed in RLT buffer, and RNA was
purified following manufacturer's instructions (Qiagen). DNase treatment
(Qiagen) was done to remove any contaminating genomic DNA. Total RNA (1
p,g) was reverse transcribed using murine leukemia virus reverse transcriptase
(Life Technologies, Bethesda, MD) with oligo(dT) as primer (Invitrogen, San
Diego, CA). All cDNA samples were ali quoted and stored at -20°C until
further use. PCR was performed in PTC-100 Programmable Thermal
Controller (MJ Research, Cambridge, MA) using Hot Start PCR Master Mix
(Promega, Madison, WI). The primers used were murine GAPDH (forward:
and

CATCCTGCACCACCAACTGCTTAG
GCCTGCTTCACCACCTTCTTGATG);
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murine

reverse:
gp80

(forward:

reverse:

TGTCAACGCCATCTGTGAGTGG
ACTTTCGTACTGA TCCTCGTGG);

murine

CAGCGTACACTGATGAAGGTGGGAAAGA

gp130

(forward:
reverse:

GCTGACTGCAGTTCTGCTTGA).

Cytokine ELISA of cell culture supernatant

Following 24 hrs of in vitro stimulation, the supernatant was collected and
used immediately or stored at -80°C until further use. Lysates were analyzed
using a standard sandwich ELISA protocol. Anti-VEGF capture and
biotinylated detection Abs and recombinant standards for murine VEGF 164
were from R&D Systems. The color reaction was developed using 2,2' -azino
bis-3 ethylbenzthiazoline-6-sulfonic acid) (Sigma-Aldrich) and measured with
an ELISA reader (Spectramax 340; Molecular Devices, Sunnyvale, CA) at 405
nm. The detection limit was 2 pglrnl. Quantification was performed with
Spectramax ELISA reader software version 1.2.

Intracellular staining and flow cytometry

Single cell suspensions were prepared from four corneas at 12 and 24 h post
injection, as described elsewhere (12), with some modifications. Briefly,
corneal buttons were incubated with collagenase D (Roche) for 60 min at 37°C
in a humidified atmosphere at 5% C02. After incubation, corneas were
disrupted by grinding with a syringe plunger and passing through a cell strainer.
Cells were washed and suspended in RPMI 1640 with 10% FBS. The Fc
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receptors on the cells were blocked with unconjugated anti-CDI6/32 (BD
PharMingen) for 30 min. Intracellular staining of VEGF was done as
described before (4). All samples were collected on a FACScan (BD
Biosciences, San Diego, CA), and data were analyzed using Cell Quest 3.1
software (BD Biosciences).

Quantitative real-time peR

Total RNA from four corneas per time point was extracted by using RNeasy
RNA extraction kit (Qiagen, Valencia, CA). Briefly, tissues were lysed in RLT
buffer, and RNA was purified following manufacturer's instructions (Qiagen).
DNase n-eatment (Qiagen) was done to remove any contaminating genomic
DNA. To generate cDNA, 1 /lg of total RNA was reverse transcribed using
murine leukemia virus reverse transcriptase (Life Technologies) with
oligo(dT) as primer (Invitrogen), according to manufacturer's instructions. All
cDNA samples were aliquoted and stored at -20°C until further use.

Real-time PCR was performed using a DNA Engine Opticon (MJ
Research Inc.). PCR was performed using SYBR Green I reagent (Qiagen),
according to manufacturer's protocoL PCR amplification of housekeeping
gene, murine GAPDH, was done for each sample as a control for sample
loading and to allow normalization between samples. During the optimization
procedures of the primers, 1% agarose gel analysis verified the amplification
of one of the product of the predicted size with no primer-dimer bands. The
absence of primer-dimer formation for each olignucleotide set was also
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validated by establishing the melting curve profile. The semiquantitative
comparison between samples was calculated as follows: the data were
nom1alized by substracting the differences of the threshold cycles (CT )
between the gene of interest's C T and the "house keeping" gene GAPDH's C T
(gene of interest CT - GAPDH CT = L1 CT) for each sample. The L1 CT was then
compared to the expression levels of the negative control sample (sample L1 C T
-negative control L1 CT ) (negative control samples include PBS injected eyes
in case of in vivo experiments and media only in case of in vitro experiments).
To determine the relative enhanced expression of the gene of interest, the
following calculation was made: fold change = 2
The

primers

used

for

.murine

GCCAGCACATAGAGAAATGAGC

(-sampleLl C T negative controiLl C T) .

VEGF 164

were,

and

forward
reverse

CAAGGCTCACAGTGATTTTCTGG

Statistical analysis

Unless specified, a one-tailed, paired Student's t-test has been used.

RESULTS
Uninfected resident corneal cells act as a source of VEGF at an early
stage of viral infection
To determine and characterize the cellular source of VEGF following virus
infection, mice were infected with HSV -1 RE expressing EGFP under the
control of gC promoter (HSV-1-RE-pgC-EGFP). At 24 hr p. i., corneas were
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stained for VEGF. As demonstrated in Fig lA, it is clearly evident that
uninfected corneal epithelial cells surrounding the infected ones stained
positive for VEGF. However, no double staining was observed in the infected
cells. In addition, in the single cell suspension of cornea infected with HSV-1
RE pgC-EGFP, uninfected resident corneal cells (GFP-) and not infected cells
(GFP+) were stained positive for VEGF at 24 hr p. i. (Fig. 1B and 1C). These
results indicate that production of VEGF at an early time point was a product
of uninfected resident corneal cells.

Subconjunctival injection of recombinant murine IL-6 induces VEGF in a
dose dependent manner

To establish the role of IL-6 in paracrine production of VEGF, various doses
(50ng, lOOng, 200ng and 400ng) of recombinant murine IL-6 was injected
subconjunctivally (3 mice/group). At 24 hr post injection, an approximately an
8-10 fold increase in the VEGF transcript level was detectable by Real Time
PCR (Fig. 2A). In addition, a dose dependent increase in the VEGF transcript
level also occurred following IL-6 administration (Fig. 2A). At this time point,
the VEGF transcript level was 1.8 fold (50ng), 5.9 fold (100ng), 9.8 fold
(200ng) and 10.1 fold (400ng) higher in comparison to the PBS control.
Antibody neutralization of recombinant IL-6 resulted in a dose dependent
decrease in VEGF transcript levels (Fig. 2B). In addition, at an antibody
concentration of 500ng (3.5 fold) and 5J.1g (1.4 fold) was significantly
decreased (p<O.05) in comparison to rat the IgG control (Fig. 2B).
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In additional experiments, the number of resident corneal cells
producing VEGF in response to subconjunctival injection of murine IL-6
(200ng) was quantified. As demonstrated in Fig. 2C, 0.9 ± 0.3% and 1.5 ±
0.2% of cells were VEGF at 12 and 24 hr post injection respectively. In
addition antibody neutralization of IL-6 resulted in a_significant (p<O.05)
decrease in the number of VEGF cells in comparison to the rat IgG control.
These experiments suggest that IL-6, normally produced post HSV-1
infection, can in itself induce the production of VEGF from resident corneal
cells.
To further delineate the possible cellular sources of VEGF following
IL-6 stimulation primary corneal epithelial cells and various cell lines that
represent cellular components of the cornea were stimu1ated in vitro with
various doses of recombinant IL-6 for 24 hrs. All the cells investigated
expressed both the gp80 and gp130 transcripts of the IL-6 receptor (Fig 3).
As shown in Fig 4A and B, corneal epithelial cells and stromal
fibroblast cells respond to recombinant murine IL-6 result in a dose dependent
manner to express VEGF transcript and protein levels respectively. In sharp
contrast, there was no significantjncrease in the amount of VEGF produced
from a dendritic cell line (DC 2.4) following stimulation with IL-6 for 24 hrs
(Fig 5B).
To find out whether in addition to resident corneal cells, inflammatory
cells can also produce VEGF in response to IL-6 stimulation, the macrophage
cell line (J774A.1) was stimu1ated with various concentrations of recombinant
murine IL-6. As evident from Fig. 5A, C, following 24hrs of stimulation, there
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was a dose dependent increase in the VEGF label in cell culture supernatant.
The VEGF level was significantly higher (p<O.05) than the media control.
Intracellular staining of some of these stimulated cells revealed positive
staining for VEGF in the cytoplasm.

DISCUSSION
This present study evaluates the role of IL-6 in the initiation of corneal
angiogenesis following virus infection. Both in vivo and in vitro data indicate
that IL-6 produced from virus infected cells can stimulate noninfected resident
corneill cells and other inflammatory cells in a paracrine manner to secrete
VEGF, a potent angiogenic factor. Thus, our data substantiates the close
relationship between proinfiammatory cytokines and VEGF induced corneal
neovasc ularization.
In HSK, angiogenesis is a prominent and early feature of the
pathogenesis, with VEGF mRNA detectable by 12 hr pj. and proteins
detectable by 24 hpj. (3, 4). Interestingly only a replication competent and
not an incompetent virus have been shown to induce VEGF expression in the
cornea, indicating the essential role of viral replication in the corneal
epithelium to initiate this process (13). However, the production of VEGF
seems to be the consequence of a paracrine effect of molecules released from a
virus infected cell, as uninfected corneal cells and not infected cells stained
positive for VEGF. The above observations raise the question as to the
mechanism by which HSV infection of a cell triggers another cell to turn on
VEGF gene expression. Although productive HSV infection by virtue of virion
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host shutoff protein eliminates most host cell protein synthesis (14), evidence
suggests that some proinflammatory cytokine gene such as IL-l and IL-6 are
upregulated (15,

16,

17). Supporting this scheme, previous studies

demonstrated that shortly after HSV infection, both IL-l and IL-6 are
abundant by day 1 post infection. (5, 6). It is presently unclear as to whether,
during a corneal infection, one of two cytokines precedes the other or whether
they are both produced at the same time. However, based on the generally
accepted fact that IL-l precedes IL-6 in inflammatory cascade of events and
our previous results (7), we believe that IL-l is a critical cytokines and is
presumably upregulated very early after infection of the cornea and induces
the production of IL-6 from resident corneal cells (7). However, these
cytokines are potent stimulators of VEGF production (18, 19). Previous study
from our group demonstrated the essential role of IL-ln in VEGF production
from corneal epithelial cells (7). In addition, intrastromal injection of IL-6
results in corneal neovascularization in a VEGF dependent process (20).
Specifically, IL-6 produced from a virus infected cell can stimulate
surrounding noninfected cells to produce VEGF.
In our study the VEGF producers appeared to be two major cell types,
noninflammatory residential corneal cells and inflammatory cells. Previous
investigations have demonstrated that inflammatory cells start infiltrating
corneal stroma 48 hr pj. onwards (21). Thus, it can be assumed that early after
infection most VEGF producing cells were noninflammatory resident corneal
epithelial and stromal cells. Supporting this scheme we were able to
demonstrate that both corneal epithelium and stromal cells can produce VEGF
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in response to IL-6. The second VEGF-producing cell type was inflammatory
cells in the corneal stroma. These were the major VEGF producers in the
clinical phase, with both PMN and macrophage-like cells involved. Since virus
is usually undetectable in the stroma and is absent in the cornea after the first
few days of infection, virus itself, would seem not to be the stimulus for
VEGF production. As macrophages are seen in the clinical phase, our data
along with other findings (4) indicate that the predominant producer cell type
appeared to be noninflammatory cells in the preclinical phase, but
subsequently, in the clinical phase, macrophages and probably stromal
fibroblast in the stroma were the sites of VEGF production. In addition,
neutrophils also contribute significantly to VEGF induced angiogenesis
process by carrying preformed VEGF in their vesicles (22, 23). However, it is
not known whether IL-6 influence the neutrophil degranulation process and
thereby causing release of preformed VEGF. This issue is currently under
investigation.
Taken together, this study support the hypothesis that cytokines
induced as a consequence of viral replication play an essential role in VEGF
induced corneal neovascularization process. An important component of this
cytokine milieu, as demonstrated in this present report is IL-6. Our results
indicate that the control of angiogenesis by limiting the virus induced
inflammatory response represents a useful therapy of herpetic ocular disease,
an important cause of human blindness.
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Fig 1. Uninfected and not infected corneal epithelial cells express VEGF
following ocular infection with HSV-1 following 24 hr post infection
A. Mice were infected with HSV-l-RE-pgC-GFP. At 24 hr p. i. eyes were
frozen in OCT compound and six micron sections were made. The slides were
stained with monoclonal anti mouse biotinylated VEGF antibody and
Streptavidin APC. The slides were visualized under a confocal laser scanning
microscope (Leica, Wetzlar, Germany). Original bar 80f..1m. The single arrow
indicates the HSV -1 RE gC-GFP infected corneal epithelial cells and the
double arrow indicates VEGF cells. Epi: Epithelium; Str: Stroma
B. Mice were infected with HSV-l-RE-pgC-GFP. At 24 hr p. i. corneas were
digested and single cell suspension was made as described in Materials and
Methods. The cells were stained with monoclonal anti mouse biotinylated

VEGF antibody and Streptavidin APC. The slides were visualized under a
confocal laser scanning microscope (Leica, Wetzlar, Germany). Original bar
80f..1m. The single arrow indicates the HSV -1-RE-pgC-GFP infected resident
corneal cells and the double arrow indicates VEGF cells.
C. At 24 hr p. i. single cell suspensions were made from HSV -1-RE-pgC-GFP
infected corneas. Numbers of cells expressing GFP (virus infected) out of total
VEGF cells were enumerated by FACS analysis. The dot plot represents one
of three separate experiments.
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Fig 2. Subconjunctival injection ofrecombinant murine IL-6 stimulates
resident corneal cells to produce VEGF
A. At 24 hr post injection four corneas/group were processed for the extraction
of cellular total RNA. Real-time PCR analysis was conducted to detect the
VEGF mRNA expression in corneas of mice injected with different doses of
recombinant IL-6 as described in Materials and Methods. LPS (lJlg/ml) was
injected subconjuctivally as positive control. Results are shown as mean ± SD
of three separate experiments. * Significant difference in comparison to PBS
control.
B. For antibody neutralization of IL-6, 200ng of recombinant murine IL-6 was
mixed with various doses of anti IL-:-6 antibody and injected subconjunctivally.
At 24 hr post injection four corneas/group were processed for the extraction of
cellular mRNA. Real-time PCR analysis was conducted to quantify the VEGF
mRNA in corneas of mice injected with different doses of recombinant IL-6 as
described in Materials and Methods. Results are shown as mean ± SD of three
separate experiments. "'Significant differences in comparison to rat IgG
control.
C. At 24 hr post injection 6 corneas/ group were collected and made into
single cell suspension. The cells were counted and intracellular staining was
done with anti murine biotinylated VEGF antibody and streptavidin PE. The
number of VEGF+ cells was enumerated by FACS analysis. The dot plot
represents one of the three separate experiments. The number in the right hand
comer represents percentage of VEGF cells out of total corneal cells.
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Fig 3. Unmanipulated corneal epithelial cells, MKT-l, DC2.4 and J774A.l
cell lines express transcripts for functional IL-6 receptor
Total RNA was extracted and was converted into cDNA, as described in

Materials and Methods. PCR was performed in PTC-100 Programmable
Thermal Controller (MJ Research). Murine GAPDH served as internal control.

Lane M: molecular weight marker.
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Fig 4. lnterleukin 6 stimulation of corneal epithelial cells and stromal
fibroblast result in the expression of VEGF transcript and protein
respectively
A. Murine corneal epithelial cell sheet was isolated from naIve mice as
described in Materials and Methods. The epithelial cell sheets were then
placed in DMEM without sera containing various concentrations of
recombinant murine IL-6 for 24 hrs at 37° C. After incubation total RNA was
extracted and converted to CDNA. Real-time PCR analysis was conducted to
detect the VEGF mRNA expression in corneal epithelial cells stimulated with
different doses of recombinant IL-6 as described in Materials and Methods.
Results are shown as mean ± SD of three separate experiments. * Significant
increase in comparison to media control.
B. Stromal fibroblast cell line (MKT-1) was stimulated with various doses of
murine recombinant IL-6 for 24 hrs. After incubation the supernatant was
collected and amount of VEGF protein in the supernatant was estimated using
a sandwich ELISA as outlined in Materials and Methods. LPS (lJlglml) was
used as positive control. Results are expressed as mean ± SD of three separate
experiments. * Significant increase in comparison to media control. The
horizontal line represents the constitutive production of VEGF (media
control).
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Fig 5. Macrophage cell line (J774A.l) produces VEGF following in vitro
stimulation with various doses ofrecombinant murine IL-6
A. Macrophage cell line (J774A.1) was stimulated with various doses of
murine recombinant IL-6 for 24 hrs. After incubation the supernatant was
collected and amount of VEGF protein in the supernatant was estimated using
a sandwich ELISA as outlined in Materials and Methods. LPS

(1~glml)

was

used as positive control. Results are expressed as mean ± SD of three separate
experiments. * Significant increase in comparison to media control. The
horizontal line represents the constitutive production of VEGF (media
control).
B. Dendritic cell line (PC2.4) was stimulated with various doses of murine
recombinant IL-6 for 24 hrs. After incubation the supernatant was collected
and amount of VEGF protein in the supernatant was estimated using a
sandwich ELISA as outlined in Materials and Methods. LPS (1 ~glml) was
used as positive control. Results are expressed as mean ± SD of three separate
experiments.
C. Macrophage cell line (J774A.1) was stimulated with 200ng of murine
recombinant IL-6 for 24 hrs. Following incubation intracellular staining was
done to detect the VEGF using anti murine biotinylated VEGF antibody and
streptavidin Alexa-flour. A total volume of

100~1

cell suspension containing

5x104 cells was spun down using a cytospin. The slides were visualized under
a confocal microscope (Leica, Wetzlar, Germany). Original magnification x
200
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PART IV

ROLE OF IL-l INDUCED COX-2 IN OCULAR
IMMUNOPATHOLOGIC DISEASE;
HERPETIC STROMAL KERATITIS
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Research described in this chapter is a slightly modified version of an article
submitted for publication in The Journal of Immunology by Partha Sarathi
Biswas, Kaustuv Banerjee, Bumseok Kim, Paul R. Kinchington and Barry T.
Rouse.

In this chapter "we" and "our" refers to co-authors and me. My contributions
in the paper include (1) selection of the topic (2) data analysis and
interpretation (3) planning experiments (4) compiling and interpretation of the
literature (5) understanding how results fit with the literature (7) compilation
of contributions into one paper (8) providing structure to the paper (9) making
graphs, figures and tables (10) writing and editing.

ABSTRACT
Ocular infection with Herpes simplex virus (HSV) results in a blinding
immuno-inflammatory lesion known as herpetic stromal keratitis (SK). Early
preclinical events include PMN infiltration and neovascularization in the
corneal stroma. In this report, we demonstrate that HSV infection of the
cornea results in the upregulation of the Cycloxygenase 2 enzyme (COX-2).
The likely source of COX-2, at least initially after infection, was stromal
fibroblasts. This enzyme was shown to contribute to the early inflammatory
and neovascularization process in response to HSV infection through
upregulation of prostanoids. Inhibition of COX-2 with a selective inhibitor
was shown to reduce corneal angiogenesis and HSK severity. The
administration of a COX-2 inhibitor resulted compromised PMN infiltration
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into the cornea. In addition, the treatment diminished corneal vascular
endothelial growth factor levels, likely accounting for the reduced angiogenic
response. Since early pro inflammatory events and angiogenesis appears to
represent a critical step in the pathogenesis of SK, these results indicate that
targeting COX-2 for inhibition should prove useful for the therapy of herpetic
SK.

INTRODUCTION
Herpetic stromal keratitis (HSK) is a blinding immunopathological reaction
that results from ocular infection with Herpes simplex virus 1 (HSV -1) (1).
This results mainly froJ;Il a chronic inflammatory reaction in the normally
transparent and avascular cornea. Studies with the murine model have
revealed a complicated pathogenesis, the critical event being the influx of
CD4+ T cells (2, 3). Prior to the T cell-mediated immunoinflammatory phase,
multiple events occur after virus infection that set the stage for the subsequent
pathology. These events include the production of proinflammatory mediators,
prominent invasion of the cornea by polymorphonuclear leukocytes (PMN)
and corneal angiogenesis (4). However the factors responsible to initiate the
inflammatory and angiogenic events in the corneal stroma following virus
infection remain poorly understood. Previous studies demonstrated that HSV
replication, which in the mouse model is usually confined to the corneal
epithelium, results in the production of proinflammatory cytokines and
chemokines, creating an environment favorable for cell influx and
angiogenesis in corneal stroma (4). Thus understanding these early
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inflammatory mediators that determine the subsequent outcome of this
immunopathological condition is crucial for designing potential therapeutic
approaches to counteract this blinding disease in humans.
Arachidonic acid (AA), an unsaturated fatty acid is a normal
constituent of membrane phospholipids and is released by the actions of
phospholipase A2 . AA is converted to prostaglandins (PGs) by cycloxygenase
(COX) and to leukotrienes (LTs) by 5-lipoxygenase metabolites that are
biologically very active and modulate cellular functions (5). The two isoforms
of COX, COX-l and COX-2 are encoded by two separate genes and exhibit
distinct cell specific expression, regulation and subcellular localization (5).
COX-l is a constitutive enzyme and is essential for various physiological
functions (5). In contrast, COX-2 is an inducible enzyme that is induced in a
variety of cell types by diverse stimuli (5). COX-2 induced production of
prostanoids

is

often

implicated

in

chronic

inflammatory

diseases,

characterized by edema, chemotactic factors, prostanoids, leukotrienes and
phospholipase (6, 7). Increased COX-2 induced synthesis of prostaglandins
stimulates cancer cell proliferation (8), promotes angiogenesis (9, 10), inhibits
apoptosis (11)

and increases metastatic potential (12). In addition, recent

studies demonstrated the essential role of COX-2 mediated up regulation of
prostanoids in various ocular inflammatory models (13-15).
The aim of this study was to determine whether inhibition of COX-2,
as could be achieved by using a selective COX-2 blocker, had an effect on SK
pathogenesis. Our results with ocular infection with HSV demonstrate that
selective inhibition of COX-2, but not COX-I, resulted in significantly milder
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disease and reduced corneal angiogenesis compared to control mice. This
difference in disease phenotype was an indirect event and was shown to be the
consequence of a compromised early inflammatory response. Taken together,
our results demonstrate that COX-2 mediated prostanoids production is critical
in SK pathogenesis, and that the use of NSAIDs to inhibit COX-2 represents a
valuable approach for disease control.

MATERIALS AND METHODS
Mice
Wild-type, female, 6 to 8 week old, Balb/c and C57BU6 mice were purchased
from Harlan

Sprague-D~wley

(Indianapolis, IN). Animals were sex- and age

matched for all experiments. Mice transgenic (Tg) for IL-l ra protein (T14
hemizygous line) were kindly provided by Dr. David Hirsh (Department of
Biochemistry and Molecular Biophysics, College of Physician and Surgeons,
Columbia University, New York, NY). All manipulations involving the
immunocompromised mice were performed in a laminar flow hood. All
experimental procedures were in complete agreement with the Association for
Research in Vision and Ophthalmology resolution on the use of animals in
research.

Virus
HSV-l RE (obtained from Dr. Robert Hendricks Laboratory, University of
Pittsburgh School of Medicine, PA) was used in the present study. HSV-l RE
pgC-GFP was derived in the RE strain background of HSV -1, detailed by
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Hendricks group (16) and is a null mutant at the gC locus. For construction, a
cloned Pstl-EcoRI fragment (sequences from 95811 to 96789 in wild type
HSV-1 genome) containing the gC promoter and first part of the gC open
reading frame (ORF) in the corresponding sites of puc8, was first collapsed by
digestion, blunt end generation and religation to remove Pstl, HindIII and sites
between. A NheI-XbalI fragment derived from pEGFP-N1 (Clontech, Palo
Alto, CA) was then inserted into the unique NheI site located at the sequence
encoding residue 6 of gC, resulting in an in-frame placement of the EGFP
gene immediately following the glycoprotein C first 6 residues and gC
promoter. This plasmid was linearized, co-transfected with purified HSV -1 RE
DNA into vero cells using calcium phosphate coprecipitation, and progeny
virus

with

EGFP

driven

by

the

native

gC

promoter were identified by fluorescence, plaque purified and insert confirmed
by Southern blot analysis. The virus was propagated and titrated on a
monolayer of Vero cells (American Type Culture Collection, Manassas, VA,
Cat. No. CCL81) using standard protocols (17). Infected Vero cells were
harvested, titrated, and stored in aliquots at -80 D C until used.

Corneal HSV-1 infection
Mice were ocularly infected with HSV-1 RE (5x105 pfu for Balb/c and 5x106
pfu for C57BL6) under deep anesthesia induced by intraperitoneal injection of
A vertin (Sigma-Aldrich, St. Louis, MO). Mice were lightly scarified on their
corneas with a 27-gauge needle, and a 4-pJ drop containing the required dose
of virus was applied to the eye and gently massaged with the eyelids.
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Clinical observations and angiogenesis scoring

The eyes were examined on different days post infection (p. i.) by a slit-lamp
biomicroscope (Kowa Co., Nagoya, Japan), and the clinical severity of
keratitis of individually scored mice was recorded as described previously (18).
Briefly, the clinical lesion score of SK was described as 0, normal cornea; 1,
mild haze; 2, moderate haze, iris visible; 3, severe haze, iris not visible; 4,
severe haze and corneal ulcer; and 5, corneal rupture. Angiogenesis severity
was measured as described previously (19). According to this system, a grade
of 4 for a given quadrant of the circle represents a centripetal growth of 1.5
mm toward the corneal center. The score of the four quadrants of the eye was
then summed to derive the neovessel index (range, 0-16) for each eye at a
given time-point.

Administration of COX-l and COX-2 inhibitors

For COX inhibition experiments, Balblc and C57BL6 mice were treated with
COX-1 inhibitor SC-560 (10 mg/kg/day) (Upjohns and Pharmacia, a division
of Pfizer) and COX-2 inhibitor SC-236 (10 mg/kg/day) (Upjohns and
Pharmacia, a division of Pfizer) or vehicle 0.5% methylcellulose, 0.025%
Tween 80 (Sigma) by gavages. The treatment was started a day before corneal
infection and continued till day lOp. i. These doses were recommended by the
manufacturer as being selective for effective inhibition of COX-1 and COX-2
and have been used previously (20,21).

133

In vitro stimulation of murine stromal fibroblast cell line with various
recombinant murine cytokines
For stimulation of murine stromal fibroblast cell line (MKT-1) (kindly
provided by Dr. W. Kao, Department of Ophthalmology, University of
Cincinnati, Cincinnati, OR), 105 cells/well were grown for 48 hrs in 6 well
plate containing 10% FCS-DMEM. After 48 hrs of growth the cells were
finally washed and stimulated with various concentrations of recombinant ILla,

IL-1~,

TNF-a, IL-6, IL-18, IFN-y, IL-2 and VEGF in sera free DMEM for

24 hrs. Following stimulation, total RNA was extracted and stored at -80 0 C
till further use. LPS was used as positive control and only media was used as
negative control.

Corneal micropocket assay
The murine corneal micropocket assay was done as described previously (22).
Various doses (50ng and 200ng) of recombinant mutine

IL-1~

(R&D systems)

were added to these pellets before insertion into corneal pockets (four eyes per
group). In some experiments, mice were treated with COX-2 inhibitors before
corneal micropocket assay was performed. Angiogenesis was quantitated at
day 3 post implantation under stereomicroscopy as described previously (23).
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Histopathoigy
For histopathological analysis, eyes were extirpated at day 20 pj. and fixed in
10% buffered neutral formalin. Staining was performed with hematoxylin and
eosin (H&E; Richard Allen Scientific, Kalamazoo, MI).

Immunofluorescence and Immunohistochemistry staining
For immunofluorescence staining of Gr-l + cells, at day 2 p. i., eyes were
frozen in optimum cutting temperature (OCT) compound (Miles, Elkart, IN).
Sections were stained for Gr-l + cells with fluorescein isothiocyanate (FITC)
labeled anti-mouse Gr-l+ antibody (clone RB6-8C5, BD PharMingen) and
counterstained with Vectashield mounting medium for fluorescence with
propidium iodide (Vector Laboratories, Burlingame, CA) and visualized under
a fluorescence microscope (Leica, Wetzlar, Germany).

For immunohistochemistry eyes were enucleated at the indicated time
points and snap frozen in OCT compound (Miles, Elkart, IN). Six-micron
thick sections were cut, air dried, and fixed in acetone:methanol (1: 1) at -20°C
for 10 min. Endogenous peroxidase activity was blocked using a 500/0 alcohol
solution containing 0.3% hydrogen peroxide for 15 min, and sections were
blocked with 3% BSA-PBS. For detection of COX-2, Goat Anti-Cox2 (M-19)
(Santa Cruz Biotechnology, Santa Cruz, CA) was diluted 11100 and incubated
for 1 hr at room temparature. Sections were then treated with Rabbit Anti-Goat
IgG biotinylated antibody (1/200) (Vector Laboratories, Burlingame, CA)
followed by HRP-conjugated streptavidin for 45 min (111000 dilution; Jackson
135

bn

._~

____ J

ImmunoResearch Laboratories, West Grove, PA) and 3, 3'-diaminobenzidine
substrate (Biogenex, San Ramon, CA), and counterstained with hematoxylin
(Richard Allen Scientific, Kalamazoo, MI). Irrelevant biotinylated antibody
was used as negative controls.

Enzyme-linked immunosorbent assay (ELISA) of corneal lysate
For preparation of corneal lysates, six corneas per time-point were pooled and
processed as described previously (24). Lysates were analyzed using a
standard sandwich ELISA protocoL Anti-IL-6 capture and biotinylated
detection antibodies were from BD PharMingen (clone MP5-20F3), and
standard recombinant murine (rm)IL-6 was from R&D Systems (Minneapolis,
MN). Anti-IL-la., anti-MIP-2, anti-VEGF, anti

IL-l~

and anti TNF-a. capture,

biotinylated detection antibodies and recombinant standards were from R&D
Systems.

The

color

reaction

was developed. using

2,2'-azinobis(3

ethylbenzothiazoline-6-sulfonic acid diammonium salt) (Sigma-Aldrich) and
measured with an ELISA reader (Spectramax 340, Molecular Devices,
Sunnyvale, CA) at 405 nm. Quantification was performed with Spectramax
ELISA reader software version 1.2.

Prostaglandin E2 extraction and quantification was done as per
manufacturer's protocoL Briefly, six corneas per time point were dissected
under a microscope, dipped briefly in 100 11M indomethacin in saline to stop
prostaglandin synthesis and wash off excess blood, and placed in a
homogenizer tube containing garnet beads, and 0.5 ml of ethanol. The corneas
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were homogenized using a tissue homogenizer (PRO Scientific Inc., Monroe,
CT). Protein precipitate was pelleted in a microcentrifuge, and the ethanol
layer was removed to a clean tube. The ethanol was evaporated by vacuum
centrifugation, the residue was redissolved in enzyme immunoassay (EIA)
buffer (Cayman Chemical, Ann Arbor, MI), and samples were analyzed for
PGE2 and LTB4 using an EIA kit (Cayman Chemical).

Flow cytometry

Single cell suspensions were prepared from four corneas at 48 h post infection,
as described elsewhere (25). The Fc receptors on the cells were blocked with
unconjugated anti-CD16/32 (BD PharMingen) for 30 min. Samples were
incubated with FITC-Iabeled anti-Gr-1 Ab (clone RB6-8C5; BD PharMingen)
and isotype controls for 30 min. All samples were collected on a FACScan
(BD Biosciences, San Diego, CA), and data were analyzed using Cell Quest 3.1
software (BD Biosciences).

Reverse transcriptase Polymerase chain reaction

Total RNA from MKT-1 cells was extracted by using Tri-reagent (Molecular
Biology, Cincinnati, OR). Total RNA (l Jlg) was reverse transcribed using
murine leukemia virus reverse transcriptase (Life Technologies, Bethesda,
MD) with oligo(dT) as primer (Invitrogen, San Diego, CA). All cDNA
samples were aliquoted and stored at -20°C until further use. PCR was
performed in PTC-100 Programmable Thermal Controller (MJ Research,
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Cambridge, MA) using Hot Start PCR Master Mix (Promega, Madison, WI).
The

primers

used

were

murine

GAPDH

CATCCTGCACCACCAACTGCTTAG,
GCCTGCTTCACCACCTTCTTGATG;

Forward
Reverse

murine

IL-1~

Forward

CAACCAACAAGTGATAT,

Reverse GATCCAGAGTCTCCAGCTGCA;

murine

TTCGGGAGCACAACAGAGTG;

COX-2

Forward

Reverse

TAACCGCTCAGGTGTTGCAC.

Quantitative real-time peR
Total RNA from four corneas per time point was extracted by using RNeasy
RNA extraction kit (Qiagen, Valencia, CA) according to manufacturer's
instructions. To generate cDNA, 1 Jlg of total RNA was reverse transcribed
using murine leukemia virus reverse transcriptase (Life Technologies) with
oligo(dT) as primer (Invitrogen), according to manufacturer's instructions. All
cDNA samples were aliquoted and stored at -20°C un"til further use.

Real-time PCR was performed using a DNA Engine Opticon (M]
Research Inc.). PCR was performed using SYBR Green I reagent (Qiagen),
according to manufacturer's protocol. PCR amplification of housekeeping
gene, murine GAPDH, was done for each sample as a control for sample
loading and to allow nornlalization between samples. During the optimization
procedures of the primers, 1% agarose gel analysis verified the amplification
of one of the product of the predicted size with no primer-dimer bands. The
absence of primer-dimer formation for each olignucleotide set was also
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validated by establishing the melting curve profile. The semiquantitative
comparison between samples was calculated as follows: the data were
normalized by substracting the differences of the threshold cycles (CT)
between the gene of interest's CT and the "house keeping" gene GAPDH's CT
(gene of interest CT- GAPDH CT = L1 CT) for each sample. The L1 CT was then
compared to the expression levels of the vector control sample (sample L1 CT
vector L1 CT). To determine the relative enhanced expression of the gene of
interest, the following calculation was made: fold change = 2
C

T

The

primers

used

were

murine

(-sampleLl C T - vectorLl

GAPDH

CATCCTGCACCACCAACTGCTTAG,
GCCTGCTTCACCACCTTCTTGATG;

Reverse
HSV

polymerase

CCGTACATGTCGATGTTCACC,

murine

COX-2

Forward

Forward
Reverse

ATCAACTTCGACTGGCCCTTC;
CGTTTCGCAGGTGTGGTTC,

Forward

HSV
Reverse:

gB

Forward:

ATGTCGGTCTCGTGGTGC.

TTCGGGAGCACAACAGAGTG;

Reverse

TAACCGCTCAGGTGTTGCAC; murine COX-1 Forward ACT CAC TCA
GTT TGT TGA GTC ATT C, Reverse TTT GAT TAG TAC TGT AGG GTT
AATG.

Statistical analysis
Unless specified, a one-tailed, paired Student's t-test has been used.
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RESULTS
Mice treated with COX-2 inhibitor demonstrated diminished SK severity
and corneal angiogenesis following ocular HSV-1 infection

Mice (Balb/c and C57BL6) were ocularly infected with HSV -1 RE and at
different days post infection and corneal levels of COX-I, COX-2 mRNA and
PGE2 protein were measured by Real Time PCR and ELISA respectively. As
demonstrated in Fig. 1, the kinetic study revealed a steady increase in the
COX-2 mRNA and PGE2 protein levels during the preclinical phase (till day 7
p. i.) of SK. The levels of COX-2 mRNA and PGE2 protein were below the
limit of detection in naIve corneas. However, COX-I mRNA was found to be
constitutively expressed in naIve corneas and following HSV infection no
significant (p<0.05) increase in the expression level was observed (data not
shown). Taken together these data indicate that corneal intlammation during
the preclinical phase is associated with a prompt. increase in the COX-2
expression, an enzyme essential for the synthesis of various prointlammatory
prostanoids such as PGE2.
To elucidate the essential role of COX-2 in HSK pathogenesis, three
groups of Balb/c (5xI0 5 pfu) and C57BL6 (5x106 pfu) mice were treated (till
day 10 p. i.) with COX-2 inhibitor (SC-260), COX-I inhibitor (SC-536) or
vehicle respectively. These mice were evaluated clinically for the development
of SK following ocular HSV -IRE infection over a 20 days test period. As
shown in Fig. 2A and 2C, groups of Balb/c and C57BL6 mice receiving COX
2 inhibitor demonstrated significantly (p< 0.05) reduced SK severity [mean
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score 1.4 ± 0.7 (Balb/c) and 1.0 ± 0.8(C57BL6)] in comparison to COX-1
[mean score 2.9 ± 0.8 (Balb/c) and 2.8 ± 0.9 (C57BL6)] and vehicle control
[mean score 3.4 ± 0.6 (Balb/c) and 2.7 ± 0.9 (C57BL6)] groups. In addition,
while 87.5% (Balb/c) and 62.5% (C57BL6) eyes demonstrated clinically
evident lesions (score 3 or more), only 25% (Balb/c) and 12.5% (C57BL6)
COX-2 inhibitor treated eyes developed such lesions (Fig. 2B and D).
Attempts to infect mice with a higher virus dose resulted in lethality, but still
few developed a SK score of greater than or equal to 3 in COX-2 inhibitor
treated mice (data not shown). Histopathological analysis of representative
eyes of vehicle and COX-1 inhibitor treated mice revealed severe
inflammatory changes at;ld cellular infiltration in the corneal stroma at day 20
p. i. (Fig 2E). However, in mice, treated with COX-2 inhibitor protein, only
mild, inflammatory changes and cellular infiltrations were evident (Fig 2E).
In concurrence with lesion incidence and severity, significant
differences were apparent in the average extent of angiogenesis in mice treated
with COX-2 inhibitor and vehicle only following ocular infection with HSV-1
RE (5x105 pfu for Balb/c and 5x106 pfu for C57BL6) at day 20 p. i. (Fig 3B
and D). At day 20 p. i., 10 of 16 eyes (Balb/c) and 8 of 16 eyes (C57BL6) of
vehicle treated mice had developed an angiogenesis score of greater than 10
(Fig.3A and C). In marked contrast, no eyes of COX-2 inhibitor treated
BALB/c and C57BL6 mice developed equivalent scores (Fig. 3A and C).

When the overall angiogenesis was compared in the groups of vehicle treated
and COX-2 inhibitor treated mice (Baible and C57BL6), vehicle control mice
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showed 3-4 times (day 20 p. i.) more angiogenesis than COX-2 inhibitor
treated mice (Fig. 3A and C).

IL-l~

induces COX-2 expression in murine cornea following ocular HSV

1 infection
To evaluate the cellular source of COX-2 at an early stage of virus infection,
Balb/c corneas were infected with HSV-l-pgC-GFP. After 24hr p. i., corneas
were isolated and GFP+ (infected) and GFP- (uninfected) corneal cells were
sorted by FACS and analyzed for COX-2 mRNA expression by Real Time
PCR analysis. Interestingly, uninfected corneal cells expressed significantly
(p< 0.05) higher COX-2 InRNA in comparison to infected cells (Fig 4A).

Polymerase chain reaction of GFP- (uninfected) corneal cells revealed 3000
4000 fold lesser viral mRNA (gB, tk) in comparison to GFP+ (infected) at this
time point (data not shown). In addition, by immunohistochemically we were
able to demonstrate that corneal stromal fibroblasts and few corneal epithelial
cells expressed COX-2 at 24 hr p. i. (Fig 4B).
Additional experiments were carried out to detect the factors
responsible for inducing COX-2 expression in corneal stromal fibroblasts
following viral infection. Based on previous findings, potential candidates for
inducing COX-2 were proinfiammatory cytokines. Thus a murine stromal
fibroblast cell

line

was

stimulated in

vitro by

various

doses

of

proinfiammatory cytokines known to be upregulated in murine corneas
following HSV infection (lL-la,

IL-l~,
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TNF-a, IL-6, IL-18, IFN-y, IL-2 and

VEGF). Interestingly, only

IL-1~

(in all the doses used) and TNF-a (only at

the highest dose used) induced COX-2 mRNA expression at 24 hr p. i. as
revealed by RT- PCR (data not shown). Quantitatively, Real Time PCR
analysis revealed a significant (p<O.05) and dose dependent increase in COX
2 mRNA expression in

IL-1~

treated cells (Fig. 5A). Hence,

IL-1~

produced

as consequence of corneal HSV infection (Fig. 5B) may serve as a potential
molecule to induce COX-2 and drive the early inflammatory process.
Supporting this notion, we were able to demonstrate that administration of IL
l ~ in the murine cornea by micropocket assay resulted in a significant
(p<O.05) and dose dependent increase in COX-2 mRNA level (Fig 5C).
Blocking of IL-1 ~ activity using IL-1 receptor antagonist transgenic mice
resulted in a significantly (p<O.05) diminished COX-2 mRNA and PGE2
levels in murine cornea following ocular HSV -1 infection (Fig 5D and E).

Diminished inflammatory response in mice treated with COX-2 inhibitor
during the preclinical phase of HSK

Normally, after corneal HSV -1 infection, PMN infiltrate the corneal stroma at
48 hr p. i. (26). However, in mice treated with COX-2 inhibitor and eventually
showing a reduction in SK severity, the influx of PMN was severely
compromised (Fig 6). As revealed by FACS analysis at 48 hr p. L, there was
approximately 5-6 fold reduction in the number of PMN in COX-2 treated
corneas in comparison to vehicle controls. (Fig 6).
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We reasoned that the scarce cellular influx in the treated group was a
result of a block in the induction of proinflammtory cytokines and
chemokines, as a consequence of impaired COX-2 activity. As demonstrated
in Fig 7, indeed there was a significant reduction (p< 0.05) in IL-6, IL-la,
MIP-2 and PGE2 levels during the preclinical phase. However no significant
difference was observed in IL-l

~

and TNF-a levels at these time points (data

not shown). Although the LTB4 level was reduced at day 1 p. i., there was no
significant (p< 0.05) reduction at 3 and 7 days p. i. (data not shown).

Compromised angiogenic response following ocular HSV infection in
COX-2 inhibitor treated mice
As stated above, groups of mice treated with COX-2 inhibitor showed
diminished angiogenic responses in comparison to vehicle treated controls.
These mice when tested for corneal VEGF level during the preclinical phase,
demonstrated significantly (p< 0.05) reduced levels 9f VEGF at 3 and 7 days
p. i. in comparison to vehicle controls (Fig 8A). Previous studies in tumor
systems demonstrated that IL-l ~ can induce VEGF production through
upregulation of COX-2 and prostanoids (27). To demonstrate the angiogenic
activity of COX-2 induced protanoids in murine corneas, different doses of
murine

rIL-l~

were administered by corneal micropocket assay, and the extent

of angiogenesis was measured at day 3 post implantation. Interestingly, IL-l ~
induced a dose-dependent angiogenic response (Fig. 8B). In such eyes, COX-2
protein was readily detectable by immunohistochemistry around the pellet
containing recombinant IL-l ~ protein (200ng) in corneal stroma at day 4 post
144

implantation (Fig

BC).

In addition,

IL-l ~

(200ng)

implanted eyes

demonstrated a significant (p< 0.05) increase in the corneal PGE2 and VEGF
protein levels in comparison to pellet only at this time point (Fig. BE).
Administration of COX-2 inhibitor in those mice resulted in a significant
(p<O.05) decrease in the angiogenic response (Fig BD). This decrease in
angiogenic response was associated with a reduction in corneal PGE2 and
VEGF protein levels in those corneas (Fig BE).

DISCUSSION
This study focuses on the early events in the pathogenesis of the blinding
immunoinflammatory

le~ion

SK caused by ocular infection with HSV. In this

report, we demonstrate that HSV infection of the cornea results in the
upregulation of the COX-2 enzyme. This enzyme was shown to contribute to
the inflammatory and neovascularization process in the corneal stroma
through upregulation of prostanoids. The likely source of COX-2, at least
initially after infection was corneal stromal fibroblasts. Interleukin-1 fj, a
proinflammatory cytokine produced as a consequence of HSV replication
stimulates stromal fibroblasts to produce COX-2. The present study
demonstrates for the first time, the critical role of COX-2 for herpetic SK
lesion development. Accordingly, selective inhibition of COX-2 and not
COX-l

results in significantly milder disease and reduced corneal

angiogenesis compared to control mice. This difference in disease phenotype
was an indirect event and was shown to be the consequence of a compromised
inflammatory and angiogenic response. Thus our results imply that COX-2
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plays an important role in early inflammatory phase and blocking COX-2
activity using NSAIDS could represent a valuable therapeutic approach to
control HSK.
Early after ocular HSV infection the cellular source of COX-2 was
shown to be the stromal fibroblasts. It is not clear how COX-2 expression is
induced in stromal fibroblasts following HSV replication, since the infection
appears confined to the corneal epithelium (4). Our study demonstrated that
IL-1~,

and too some extent TNF-a, produced as a consequence of HSV

replication, may stimulate stromal fibroblasts to produce COX-2. Blocking IL
1~

by IL-1 receptor antagonist protein resulted in a diminished COX-2

expression. This study, as well as others (28-30), indicated that

IL-1~

stimulated fibroblasts are potent producers of COX-2. The above observations
thus delineate the mechanism by which HSV infection of a cell triggers
another cell to turn on COX-2 gene expression. However previous studies
revealed that virus reactivation in the trigeminal ganglion is associated with
upregulation of COX-2 transcript expression (31). Thus it is unclear whether
upregulation of COX-2 is also mediated by some HSV-encoded components
released from infected cells. We are currently analyzing the role of some of
these viral encoded proteins as candidates to explain COX-2 triggering.
A prominent early event after virus infection of the cornea is the influx
of inflammatory cells into the avascular stroma, primarily PMN (26). This
influx occurs promptly after infection and most likely serves several functions.
These

include

antiviral

effects

(26,

32)

and

an

involvement

in

neovascularization (33). Our result showed that mice treated with selective
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COX-2 inhibitor have compromised neutrophil influx. This observation is in
concordance with previous findings demonstrating the essential role of COX-2
induced prostanoids in neutrophil influx and activation in various
inflammatory models such as rheumatoid arthritis, dermatitis, periodonititis
and pancreatitis (34-36). How COX-2 induced prostanoids in infected mice
cornea causes PMN influx remains unclear.
The possible signals responsible for the PMN influx are most likely
multiple and nonviral derived. Previous observations demonstrated that MIP-2,
IL-6 and IL-l are critical in early influx of PMN in the murine cornea
following virus infection (24, 37, 38) and the level of COX-2 correlates with
the expression patterns of these cytokines and chemokines (39). Thus, it is
highly likely that COX-2 induced prostanoid synthesis aid PMN influx
through upregulation of IL-l, IL-6 and MIP-2. Supporting this scheme, we
could show that mice treated with selective COX-2 inhibitors and having
compromised neutrophil influx had lower levels of corneal IL-l, IL-6 and
MIP-2. Previous observations demonstrated that in humans selective inhibition
of COX-2 can prevent IL-8 mediated PMN chemotaxis at the inflammatory
site (40). This observation along with ours further strengthens the notion that
COX-2 plays a critical role in PMN chemotaxis by upregulating various
proinflammtory

cytokines

and

chemokines.

In

addition,

PMN

and

macrophages themselves serve as an additional source of COX-2 induced
prostanoids at the inflammatory site (41, 42). We anticipate that, early after
infection, COX-2 produced from stromal fibroblasts facilitates the influx of
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PMN, which in tum now acts as an additional source of prostanoids, thus
setting the stage for the chronic immuno-inflammatory phase.
Early PMN invasion contributes to corneal pathology because the cells
are a major source of angiogenesis factors (33, 43) and perhaps also tissue
damaging factors such as NO (44). Thus, in line with the mininlal early PMN
response noted in COX-2 inhibitor treated mice, such animals showed a
marked reduction in angiogenesis. One factor derived from PMN, as well as
from other cell types involved in neovascularization, is VEGF (43). We
demonstrated that VEGF was significantly down-regulated in COX-2 inhibitor
treated mice in comparison to control animals. This observation is in accord
with previous findings in rheumatoid synoviocyte and tumour models (9, 10).
How COX-2 induces VEGF production is not known. One explanation for
diminished angiogenic response in COX-2 inhibitor treated mice is, COX-2
induced PGE 2 itself has been shown to be proangiogenic (45). PGE2 along
with other prostanoids can stimulate the production of VEGF (39). However,
it is not clear whether this effect is direct or mediated by upregulation of other
cytokines such as IL-6, IL-l and chemokines containing E-L-R motifs. We are
currently testing such notions in our HSV angiogenesis model.
COX-2 represents a logical target for therapy, since this component
acts as a principal inflammatory and angiogenic factor in HSV induced
corneal inflammation. However, COX-2 inhibitors should be used with a word
of caution. Previous studies in Endotoxin induced uveitis (EIU) model
suggested that disturbance of the AA pathway exacerbates EID in COX-2
deficient mice (46) . This was caused by elevated LTB4 and 5-LO metabolized
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from arachidonic acid via the lipoxygenase pathway. At least, in our system
we were able to demonstrate that inhibition of COX-2 is not associated with
an increase in LTB 4 , thus justifying our approach in counteracting corneal
immunoinflammatory lesion with COX-2 inhibitors.

Taken

together,

our results

support

the

hypothesis

that the

inflammatory milieu and angiogenic stimuli created early after infection play
an important role in HSV -induced ocular lesions. An important participant of
this environment is COX-2 induced prostanoid synthesis. Blocking the effect
of COX-2 by a specific COX-2 inhibitor abrogates the cascade of events that
culminate in HSK. This regulation is indirectly mediated by down-regulating
various signaling molecules previously known to be important in HSK
pathogenesis and corneal angiogenesis. Thus targeting COX-2 could prove to
be a worthwhile therapeutic approach to control SK, an important cause of
human blindness.
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Fig 1. Kinetics ofCOX-2 mRNA and PGE2 leveis in HSV-l infected corneas
of Balh/c and C57BL6 mice
A. At 1, 3, and 7 days postinfection, four corneas/group were processed
for the extraction of cellular mRNA. Real-time PCR analysis was
conducted to detect the COX-2 mRNA expression in corneas of mice
infected HSV-1 , as described in Materials and Methods. Results are
shown as mean ± SD of three separate experiments.
B. Levels of PGE2 were estimated from corneas (6 corneas/ time point)
of mice infected with HSV-1 RE by a competitive ELISA, as
outlined in Materials and Methods. Results are expressed as mean ±
SD of three separate experiments (6 corneas/time point).
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Fig 2. Mice receiving COX-2 inhibitors show reduced HSK severity

A. Mean lesion HSK score at day 20 p. i. of mice infected with 5 x 105
PFU (Balb/c) HSV-1 RE. Each dot represents the HSK score from one
eye. Horizontal bars and figures in the parentheses indicate the mean
for each group.
B. Bar diagram demonstrates the percentage severity of each group of
Balb/c mice infected with 5x105 pfu at day 20 p. i. Figure in the
parenthesis represents the percentage of eyes showing HSK score
greater than or equal to 3.
C. Mean lesion HSK score at day 20 pj. of mice infected with 5 X 106
PFU (C57BL6) HSV -1 RE. Each dot represents the HSK score from
one eye. Horizontal bars and figures in the parentheses indicate the
mean for each group.
D. Bar diagram demonstrates the percentage severity of each group of
C57BL6 mice infected with 5x106 pfu at day 20 p. i. Figure in the
parenthesis represents the percentage of eyes showing HSK score
greater than or equal to 3.
E. Mice (Balb/c) were infected with 5 x 105 pfu HSV-1 RE. Mice were
terminated at day 20 pj., and eyes were processed for paraffin
embedding. H&E staining was carried out on 6 p, sections. Original
magnification, x200.
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Fig 3. Mice receiving COX-2 inhibitor show diminished angiogenic response
following HSV-l infection at day 20 p. i.
A. Angiogenesis scores for individual eyes of different groups of Balb/c
mice infected with 5 x 105 PFU HSV-1 RE at day 20 pj. Horizontal
bars and figures show the mean for each group.
B. At day 20 pj., extensive growth of blood vessels can be seen in Balb/c
mice receiving vehicle or COX-1 inhibitor and infected with 5

x

105

PFU HSV-l RE. Mice receiving COX-2 inhibitor show minimum
angiogenic sprouts near the limbal ring with the same dose.
C. Angiogenesis scores for individual eyes of different groups of C57BL6
mice infected with 5 x 106 PFU HSV-1 RE at day 20 pj. Horizontal
bars and figures show the mean for each group.
D. At day 20 pj., extensive growth of blood vessels can be seen in
C57BL6 mice receiving vehicle or COX-1 inhibitor and infected with
5 x 105 PFU HSV-1 RE. Mice receiving COX-2 inhibitor show
minimum angiogenic sprouts near the limbal ring with the same dose.
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Fig 4. Uninfected stromal fibroblasts are the major producers of COX-2
following ocular HSV-J infection.
A. Mice (Balb/c) were infected with 5xl05 PFU HSV-l-RE- pgC-GFP.
At 24 hr p. i. corneas, GFP+ cells (infected) were sorted out from
GFP- cells (uninfected) and total RNA was extracted. Real-time PCR
analysis was conducted to detect the COX-2 mRNA expression in
corneas of mice infected HSV-1, as described in Materials and
Methods. Results are shown as mean ± SD of three separate
experiments. *, Statistically significant differences (p < 0.05) in
comparison to GFP+.
B. Immunohistochemistry for COX-2 expression in corneas of Balb/c
mice. (arrows) are detectable in corneal stroma of Balb/c mice
infected with high, 5 x 105 PFU HSV-1 RE at day 1 poi.
Diaminobenzidine was used as substrate, and sections were
counterstained with hematoxylin. Original magnification x200.
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Fig S. IL-1P induced COX-2 expression in murine stromal fibroblast cell
line.
A. Murine stromal fibroblast cells were stimulated with different doses
of murine rIL-l (3 for 24 hr. After 24 hr post stimulation cells were
collected and total RNA was extracted. Real-time PCR analysis was
conducted to detect the COX-2 mRNA expression in corneas of mice
infected with HSV-l, as described in Materials and Methods. Results
are shown as mean ± SD of three separate experiments. *,
Statistically significant differences (p < 0.05) in comparison media
controL
B. Mice (Balb/c) ~ere infected with 5xl05 PFU HSV-l-RE. At different
days p. i. 4 corneas/time point were taken and total RNA was
extracted. Reverse transcriptase was conducted to detect the IL-l (3
mRNA expression in corneas of mice infected with HSV-1, as
described in Materials and Methods.
C. Different concentrations of rIL-l(3 (50, 200 ng) were administered in
Balb/c corneas (n = 8) by corneal micropocket assay. Real-time PCR
analysis was conducted at day 1 p. i. to detect the COX-2 mRNA
expression in corneas of mice infected HSV-1, as described in

Materials and Methods. Results expressed as mean ± SD.
Statistically significant differences (p < 0.05) in comparison to only
pellet.
D. Control C57BL6 mice and IL-l ra Tg mice were infected with 5xl06
pfu HSV-1 RE. At 1, 3, and 7 days postinfection, four corneas/group
167

were processed for the extraction of cellular mRNA. Real-time PCR
analysis was conducted to detect the COX-2 mRNA expression in
corneas of mice infected HSV-1, as described in Materials and

Methods. Results are shown as mean ± SD of three separate
experiments. ., Statistically significant differences (p < 0.05) in
comparison to control animals.
E. Control C57BL6 mice and IL-1 ra Tg mice were infected with 5x106
pfu HSV -1 RE. At 1, 3, and 7 days p. i., levels of PGE2 were
estimated from corneas (6 corneas! time point) of mice infected with
HSV-1 RE by a competitive ELISA, as outlined in Materials and

Methods. Results are expressed as mean ± SD of three separate
experiments (6 corneas/time point). ., Statistically significant
differences (p < 0.05) in comparison tocontrol animals.
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Fig 6. Reduced PMN influx in COX-2 inhibitor treated mice at 48 hr. p. i.
Single-cell suspensions of corneal cells were prepared from four eyes
at 48 h p. i. The cells were counted and stained with FITC-Iabeled anti
Or-I antibody, and numbers of Or-I-positive cells were enumerated by
fluorescein-activated cell sorter (FACS). Dot-plot is representative of
one of three separate experiments. The number on the upper-right
comer represents the percentage of Or-I + cells of total corneal cells at
48 h p. i.
At 48hr p. i. frozen sections (61l) of Balb!c mice cornea were stained
for PMN with FITC labeled Gr-I antibody as described in Materials
and Methods. Counterstaining was done with Propidium Iodide.
Arrows show Or-I + cells in the corneal stroma. Original magnification
x 200.
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Fig 7. Reduced levels of Cytokines and Prostanoids in the cornea of COX-2
inhibitor treated mice

At indicated time-points, six corneas/group were processed for
measuring the IL-6, IL-1a., MIP-2 and PGE2levels. Levels of IL-6, ILla., MIP-2 and PGE2 were estimated from supernatants of corneal
lysates of mice infected with 5 x 105 pfu HSV -1 RE by an antibody
capture ELISA, as outlined in Materials and Methods. Results are
expressed as Mean ± SD of three separate experiments (six
corneas/time-point).
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Fig 8. Compromised angiogenic responses in COX-2 inhibitor treated mice
A. At indicated time-points, six corneas/group were processed for
measuring the VEGF level. Level of VEGF was estimated from
supernatants of corneal lysates of mice infected with 5 x 105 pfu
HSV-1 RE by an antibody capture ELISA, as outlined in Materials
and Methods. Results are expressed as Mean ± SD of three separate
experiments (six corneas/time-point). *, Statistically significant
differences in comparison to vehicle control.
B. Different doses of recombinant murine IL-1 ~ was implanted in
corneal stroma by micropocket assay and extent of angiogenesis was
measured at day 3 post implantation as described in Materials and
Methods. *, Statistically significant differences in comparison to
pellet only.
C. Recombinant murine IL-1 ~ (200ng) was implanted in corneal stroma
by micropocket assay and at day 3 post implantation frozen sections
(6Jl) of those implanted corneas were made. These sections were

stained for COX-2 by immunohistochemistry as described in
Materials and Methods. Diaminobenzidine was used as substrate,
and sections were counterstained with hematoxylin. Original
magnification x200.
D. Reconlbinant mOline IL-1 ~ (20Ong) was implanted in corneal stroma
of COX-2 inhibitor treated and vehicle control mice by micropocket
assay. At day 3 post implantation extent of angiogenesis was
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measured as described in Materials and Methods. *, Statistically
significant differences in comparison to vehicle control.
E. Recombinant murine IL-l p (200ng) was implanted in corneal stroma
of COX-2 inhibitor treated and vehicle control mice by micropocket
assay. At day 3 post implantation 6 corneas/group was processed for
measuring the VEGF and PGE2 level. Results are expressed as Mean
± SD of two separate experiments (6 corneas/time-point). * **,

Statistically significant differences in comparison to vehicle control
and COX-2 inhibitor treated group.
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PART V

COUNTERACTING CORNEAL
IMMUNOINFLAMMATORY LESION WITH
INTERLEUKIN- 1 RECEPTOR ANTAGONIST
PROTEIN

177

Research described in this chapter is a slightly modified version of an article
published in 2004 in Journal of Leukocyte Biology by Partha Sarathi Biswas,
Kaustuv Banerjee, Mei Zheng and Barry T. Rouse.

Biswas, P. S., K. Banerjee, M. Zheng, and B. T. Rouse. 2004. Counteracting
corneal immunoinflammatory lesion with interleukin-l receptor antagonist
protein. J Leukoc BioI. 76(4):868. Copyright 2004. The American Association
of Immunologists, Inc.

In this chapter "we" and "our" refers to co-authors and me. My contributions
in the paper include (1) selection of the topic (2) data analysis and
interpretation (3) planning experiments (4) compiling and interpretation of the
literature (5) understanding how results fit with the literature (7) compilation
of contributions into one paper (8) providing structure to the paper (9) making
graphs, figures and tables (10) writing and editing.

ABSTRACT
Herpetic

Stromal

Keratitis

(HSK)

is

a

T

cell

orchestrated

immunointlammatory lesion that results from corneal HSV infection. Previous
reports indicate an essential role for proinflammatory cytokine IL-l in HSK
pathogenesis. The present study evaluates the efficacy of IL-l receptor
antagonist (lL-l ra) protein in the management of HSK. Mice receiving IL-l
ra had diminished disease sevelity. The administration of IL-l ra was shown
to reduce the influx into the cornea of cells of both the innate and adaptive
178

immune response. In addition, the treatment also diminished corneal VEGF
levels resulting reduced angiogenic response. Our results show the importance
of targeting early proinflammatory molecules such as IL-l to counteract HSK
and advocate IL-l ra as an effective agent to achieve this.

INTRODUCTION
In almost 20% of individuals with a Herpes simplex virus (HSV) infection a
blinding immunoinflammmatory lesion, called herpetic stromal keratitis
(HSK), develops (1). Management of HSK usually requires indefinite
corticosteroid therapy (2). In some cases corneal damage results in permanent
loss of vision necessitating transplantation. Studies with the murine model
have revealed a complicated pathogenesis, the critical event being the influx of
CD4+ T cells (3, 4). Leading to the influx of these crucial cells are several
events that include proinflammatory cytokine and chemokine production,
influx of innate immune cells and angiogenesis (5-7). Both IL-l and IL-6 are
likely the mediators of corneal inflammation (8-10), and have been recently
demonstrated as essential in the pathogenesis of corneal disease following
HSV-1 infection (11).
To test our hypothesis that IL-l represents one of the first mediators to
initiate the inflammatory cascade, we blocked its activity using the IL-l
receptor antagonist protein (IL-l ra). The IL-l ra protein is a naturally
occurring isoform of IL-l and can bind to IL-l receptors with high-affinity but
fails to induce signal transduction (12). The protein is routinely used in
treatment of human immunoinflammatory conditions such as rheumatoid
179

arthritis (13). Interleukin -1

receptor antagonist protein administered

systemically down regulates cytokine production in humans and rats (14-16).
In the ocular alkali bum murine model, IL-l ra has been shown to have a
therapeutic potential (16). We show using a combination of systemic and local
IL-l ra administration, that the severity of corneal angiogenesis and HSK is
diminished following ocular HSV infection. This was a consequence of a
down regulation of various inflammatory mediators, normally induced by IL-l
in HSV infected corneas. Thus blocking IL-l activity using IL-l ra protein
could represent a valuable therapeutic approach in managing HSK.

MATERIALS AND METHODS
Mice
Wild type female 6 to 8 weeks old C57BU6 mice were purchased from Harlan
Sprague-Dawley (Indianapolis, Indiana). Animals were sex and age matched
for all experiments. Mice transgenic for IL-l receptor antagonist protein (T14
hemizygous line) were kindly provided by Dr. David Hirsh (Department of
Biochemistry and Molecular Biophysics, College of Physician and Surgeons,
Columbia University), All manipulations involving the immunocompromized
mice were performed in a laminar flow hood. All experimental procedures
were in complete agreement with the Association for Research in Vision and
Ophthalmology (ARVO) resolution on the use of animals in research.
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Virus
HSV-1 RE (obtained from Dr. Robert Hendricks Laboratory, University of
Pittsburgh School of Medicine) was used in the present study. The virus was
propagated and titrated on monolayer of Vero cells (ATCC, Cat No. CCL81)
using standard protocols (17). Infected Vero cells were harvested, titrated and
0

stored in aliquots at _80 C until used.

Corneal HSV..1 infection
Mice were ocularly infected with HSV -1 RE under deep anesthesia induced by
intraperitoneal injection of Avertin (Sigma-Aldrich, St. Louis, MO). Mice
were lightly scarified on their corneas with a 27-gauge needle and a 4J.tl drop
containing the required dose of virus was applied to the eye and gently
massaged with the eyelids.

Clinical observations and Angiogenesis Scoring
The eyes were examined on different days post infection by a slit-lamp
biomicroscope (Kowa Co. Nagoya, Japan), and the clinical severity of keratitis
of individually scored mice was recorded as described before (11).
Angiogenesis severity was measured as described previously (18). Briefly, a
grade of 4 for a given quadrant of the circle represents a centripetal growth of
1.5mm toward the corneal center. The score of the 4 quadrants of the eye were
then summed to derive the NV index (range 0-16) for each eye at a given
point.
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Subconjunctival inoculations
Subconjunctival inoculation of recombinant human IL-l

ra protein

[0.5mg/cornea, Img/cornea] (supplied by Amgen Inc., Thousand Oaks, CA)
was performed as described previously (8). Briefly, subconjunctival
inoculations were done using a 2 em 32 gauge needle and syringe (Hamilton,
Reno, NV) to penetrate the perivascular region of conjunctiva and required
dose of IL-l ra protein was delivered into the subconjunctival space. Control
mice received 0.2% sodium hyaluronate in PBS only. Mice received
recombinant human IL-l ra one day before corneal infection with HSV -1.

Alzet infusion pump implantation
Alzet osnl0tic punlps (Palo Alto, CA) were used to deliver IL-l ra
subcutaneously as described before (19). Briefly, the micro-osmotic pumps
(Model 1007D) were implanted 24 hr before ocular infection. The pumps were
loaded with IL-l ra or vehicle as per the manufacturer's instructions under
sterile condition. The mice were weighed, marked and anaesthetized using
Isoflurane (Abbott Laboratories, North Chicago, IL). Mice were placed into
dorsal recumbancy, clipped over the shoulder area and prepared for the
surgery. A small 1 em incision was made caudal to the shoulder area, the skin
was undermined with a hemostat and then the pump was placed into the
prepared pocket. Skin was then closed with 9 mm autoclips (Braintree
Scientific Inc., Braintree, MA). The pump was taken out after 7 days and the
skin was closed again with 9mm clips. With a mean pumping rate of 0.5flllhr
(mean fill volume of IOOfll), calculated drug infusion rates were 5mg/kg
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b.wtlhr for 7days, 2.Smglkg b.wtlhr for 7days and Imglkg b.wtlhr for 7days.
Control mice received osmotic pumps with vehicle only for the same period of
time.

Histopatholgy

For histopathological analysis, eyes were extirpated at day 20 p. i. and fixed in
10% buffered neutral formalin. Staining was performed with Hematoxylin and
Eosin (Richard Allen Scientific, Kalamazoo, MI).

Immunofluorescence staining

For immunofluorescence staining, at day 20 p. i. eyes were frozen in optimum
cutting temperature (OCT) compound (Miles, Elkart, IN). Six micron thick
sections were cut, air dried and fixed in acetone for 20 minutes at 4 0 C. The
sections were blocked with 3% BSA (Sigma) containing unconjugated anti

CD16/32 (1 :200) antibody (BD Pharmingen, San Diego, CA) for 3 hours at
37 0 C. For detection of CD4+ T cells, the sections were incubated with FITC
labeled anti mouse CD4+ antibody (Clone RM4-S, Pharmingen) in 1% BSA at
4 0 C overnight. Sections were repeatedly washed in PBS and mounted with
Vectashield mounting medium for fluorescence with Propidium Iodide
(Vector Laboratories Inc. Burlingame, CA) and visualized under a microscope
(Leica, Wetzlar, Germany).
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Flow Cytometry

Single-cell suspensions were prepared from 4 corneas at different days post
infection as described elsewhere (20), with some modifications. Briefly,
corneal buttons were incubated with collagenase D (Roche, Mannheim,
Gennany) for 60 min at 37°C in a humidified atmosphere at 5% CO 2 . After
incubation, eyes were disrupted by grinding with a syringe plunger and
passing through a cell strainer. Cells were washed and suspended in RPMI
1640 with 10% PBS. Blocking was done with unconjugated anti-CD16/32
(Phanningen) for 30 min. Samples were incubated with FITC labeled anti Gr
1 antibody (Clone RB6-8C5, Phanningen), FITC labeled anti CD4 antibody
(Clone RM4-5, Phanningen) and isotype controls for 30 minutes. All samples
were collected on a FACScan (BD Biosciences, San Diego, CA), and data
were analyzed using CellQuest 3.1 software (BD Biosciences).

Cytokine ELISA of corneal lysate

For preparation of corneal lysates, 6 corneas per time point were pooled and
minced. All procedures were done on an ice bath. Minced pieces were
collected in 1ml DMEM without FCS and homogenized using a tissue
homogenizer (PRO Scientific Inc., Monroe, CT) four times, 15 seconds each,
with a gap of 1 minute between homogenization to allow the sample to cool.
The lysate was then clarified by centrifugation at 14,000 rpm for 5 minute at
D

D

4 C. The supernatant was collected and used immediately or stored at _80 C
until further use. Lysates were analyzed using a standard sandwich ELISA
protocol. Anti IL-6 capture and biotinylated detection antibodies were from
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Pharmingen (Clone MP5-20F3) and standard recombinant murine IL-6 was
from R&D Systems Inc, Minneapolis. Anti MIP-2 and anti VEGFl64 capture
and biotinylated detection antibodies and recombinant standards for murine
MIP-2 and murine VEGFl64 were from R&D Systems. For detection of
recombinant human IL-l ra, anti human IL-l ra capture and detection antibody
and recombinant human IL-l ra were obtained from R&D Systems Inc.
Minneapolis. The color reaction was developed using ABTS (Sigma) and
measured with an ELISA reader (Spectramax 340, Molecular Devices,
Sunnyvale, CA) at 405nm. Quantification was performed with Spectramax
ELISA reader software version 1.2.

Statistical analysis
Unless specified a standard student's t test has been utilized.

RESULTS
Subconjunctival administration of IL-l ra protein has no effect on HSK
severity and corneal angiogenesis
To evaluate whether local administration of IL-l ra protein modulates HSK
severity and corneal angiogenesis following ocular HSV infection, three
groups of mice were subconjunctivally injected with 0.5mg/cornea,
Img/cornea and vehicle only, 24 hour before corneal infection. At day 3, 5 and
7 days post injection corneal levels of recombinant IL-l ra protein was
determined by ELISA. As demonstrated in Fig 1, IL-l ra protein was
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detectable in both the treated groups at day 3 post injection only. However,
levels of IL-l ra protein were undetectable at 5 and 7 days post infection.
Mice

receiving

subconjunctival

injection

of 0.5mg/cornea,

1

mg/cornea of IL-l ra protein and vehicle were assessed clinically for the
development ofHSK following HSV-l RE (5xl06 pfu) ocular infection over a
20 days test period. Mice transgenic for the IL-l ra protein were used as a
positive control. As shown in Fig 2A, there was no difference in the severity
of HSK in both treated and vehicle control mice [mean scores 2.9 ± 1.0
(0.5mg/cornea), 2.8 ± 1.2 (lmg/cornea) and 2.9 ± 1.1 (vehicle)]. In sharp
contrast, mice transgenic for IL-l ra protein demonstrated markedly reduced
HSK severity (mean score of 1.3 ± 0.9) (Fig. 2A). Further, whereas treated and
control groups showed clinically evident lesions (HSK score of 3 or more) in
56.3% (0.5mg/c ornea) , 50% (lmg/cornea) and 62.5% (vehicle control) of
eyes, only 18.9% of IL-I ra Tg eyes developed lesions (Fig 2B).
Histopathological analysis of representative eyes of. both treated and control

C57BU6 mice revealed severe inflammatory changes and cellular infiltration
in the corneal stroma at day 20 p. i. (Fig. 2C). However, in mice transgenic
for IL-I ra protein only mild inflammatory changes and cellular infiltrations
were evident (Fig. 2C).
No significant difference (p< 0.05) was observed in the extent of
angiogenesis between IL-l ra treated and control mice (Fig. 3A and C).
However, mice transgenic for IL-l ra protein showed significantly (p<0.05)
reduced corneal neovascularization in comparison to treated and control
groups (Fig. 3A and C). By day 20 p. i, an angiogenesis score of 10 or greater
186

was observed in 8 of 16 vehicle control eyes, and in eyes receiving
Img/cornea and O.5mg/cornea. Only 2 of 16 eyes of IL-I ra Tg mice
developed such a score (Fig 3B). Taken together, these results indicate that
administering IL-I ra protein locally has no effect in modulating either
angiogenesis or keratitis.

A combination of systemic and subconjunctival IL-l ra administration
diminishes HSK severity and corneal angiogenesis
A reason for the inability of subconjunctival administration in modulating
HSK severity may be attributed to the short persistence of IL-I ra in the
cornea. To achieve biologically active concentrations for a sustained period in
the corneal microenvironment, different doses of IL-I ra recombinant protein
were administered systemically via subcutaneous osmotic pump implantation
for 7 days. In addition, mice also received a subconjunctival injection
(lmg/cornea) (the highest concentration that could be achieved by
subconjunctival injection). With this approach the IL-I ra protein was
detectable in the cornea by ELISA till day 7 post injection (last time point
analyzed) (Fig 4). In addition, serum levels of the protein in treated mice were
significantly higher than vehicle treated animals (data not shown).
Four groups of mice were injected with 5mg/kg body wt. Ihr for 7 days
Sic + Img/cornea local (Group 1), 2.5mg/ kg body wt. Ihr for 7days Sic +

Img/cornea local (Group 2), Img/ kg body wt. Ihr for 7days Sic + Img/cornea
local (Group 3) of IL-I ra and vehicle control (Group 4) respectively. Twenty
four hours later mice were ocularly infected with 5xI06 pfu HSV-I RE. Mice
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transgenic for IL-l ra protein were used as positive control. These mice were
evaluated clinically for the development of HSK following HSV-l (5xl06 pfu)
corneal infection over a 20 days test period. As shown in Fig 5A, the severity
of HSK in Groups 1 and 2 was significantly diminished (mean score of 1.3 ±
0.9 and 1.4

± 1.0 respectively)

in comparison to Group 4 (mean score 2.9

±

1.1). The severity in former groups was almost similar to the IL-l ra Tg mice
(mean score 1.2 ± 1.1). However, the severity of HSK in Group 3 and Group 4
were similar (mean score 2.5 ± 1.1 and 2.9 ± 1.1 respectively) (Fig 5A). In
addition, whereas the incidence of disease was 56.3% of Group 4, it was only
25% of Groups 1 and 2 and 20% of IL-l Ra Tg mice (Fig 5B). Increasing the
virus dose in the transgenic animals made no difference to HSK scores (data
not shown). Histopathological analysis of representative eyes of Groups 1 and
2 and IL-l ra Tg mice revealed mild inflammatory changes in the corneal
stroma at day 20 p. i. In contrast, vehicle treated eyes developed more severe
inflammatory changes (Fig. 5C).
The extent of angiogenesis was significantly (p<0.05) lower in Group
1, Group 2 and IL-l ra Tg mice compared to vehicle treated mice (Fig 6A and
C). At day 20 p. i., while an angiogenesis score of 10 or greater was observed
in 11 of 16 vehicle control eyes, only 3 of 16 eyes in Groups 1 and 2
developed similar angiogenesis (Fig 6B). In conclusion, these results indicate
that the protein is effective only when its concentration is maintained for at
least 6-7 days after HSV -1 infection.
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Reduction in the immuno-inflammatory response post IL-! ra treatment
Normally, after a corneal HSV -1 infection, PMN infiltrate the corneal stroma
within 6hrs, with peak numbers at 24-48 hrs (5). However, in mice treated
with IL-l ra and eventually showing a reduction in HSK severity the influx of
PMN was severely compromised (Fig. 7). Thus in eyes from Group 2, PMN
numbers, as judged by Gr-l staining and flow cytometry was significantly
lower at day 2 p. i. than in vehicle control (Group 4) (3.1 ± 0.8 % compared to
21.5 ± 4.3 %) (based on previous observation we have used Group 2 for
subsequent studies). In addition, at day 20 p. i. there were very few CD4+ T
cells in the cornea of IL-l ra treated mice (12.4

± 2.3

% of total lymphocytes).

In sharp contrast, at day. 20 p. i. vehicle control mice had an abundance of
CD4+ T cells (64 ± 7.5 % of total lymphocytes) as judged by FACS analysis
and immunofluorescence staining (Fig 8A and B).
We reasoned that the scarce cellular influx in the treated group was a
result of a block in the induction of downstream events, as a consequence of
impaired IL-l activity. The prime candidates include both IL-6 and MIP-2 (8,
9). Treatment with IL-l ra (Group 2) led to a significant (p<0.05) decrease in
the corneal IL-6 protein levels at day 5 and 7 days p. i. and MIP-2 at day 2 and
5 days p. i. in comparison to vehicle control (Fig 9A and B). However, no
significant difference was observed in the protein levels of IL-ln or IL-l~
(data not shown).
As mentioned above, mice treated with 2.5mgl kg body wt. flu for
7days SIc + Imglcornea local IL-l ra protein developed significantly
diminished angiogenic response in comparison to vehicle control. Vascular
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Endothelial Growth Factor (VEGF) is one of the key players of corneal
neovascularization following ocular HSV infection (21).

To determine

VEGF levels in these treated mice, we measured corneal VEGF protein levels
at different days post infection. As expected, VEGF protein levels were
significantly (p<O.Ol) reduced in IL-1 ra treated mice at day 5 and 7 days p. i
in comparison to vehicle control (Fig 9C). Thus the reduction in the severity of
HSK seen with IL-1 ra treatment was attributable to a suppression of the
inflammatory environment, the reduction in influx of cells of the immune
system and the reduction of VEGF, a consequence of which was diminished
angiogenesis.

DISCUSSION
Using a mouse model, we have evaluated the potential of the IL-1 ra protein in
ameliorating an HSV -1 induced immuno-inflammatory corneal lesion HSK.
This study yields two important findings. First,. that blocking individual
inflammatory molecules during the early stages of corneal HSV infection
represents an alternative and effective approach to managing HSK. Second,
the IL-1 ra protein, routinely used for the treatment of other immuno
inflammatory human diseases (13), appears to be effective in ameliorating
HSK lesions. Our results also confirm the importance of the cytokine IL-1 in
the pathogenesis of HSK (11).
Both molecular and cellular events involved in HSK pathogenesis were
down regulated as a result of the IL-1 ra treatment. Blocking the IL-1 activity
resulted in a block to the induction of downstream events and thereby altered
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the environment normally conducive for the migration of inflammatory cells.
Interleukin 1, produced from HSV infected cells (22), helps in the induction of
other key cytokines such as IL-6 (23), also shown to be critical in the
pathogenesis following ocular HSV infection (23). Linked with this process is
also the production of chemokines such as IL-8 and MIP-2 (9, 16, 24), thought
to be involved in the margination and extravasation of neutrophils at the
corneal limbus. These events occur promptly following infection of the
corneal epithelium and facilitating neutrophil influx (5). In addition an
autocrine IL-l feedback loop is possibly involved in tissue remodeling in the
cornea through the induction of IL-8 (16). Interfering with these loops
therefore can alter the overall response following HSV -1 infection and prevent
tissue injury.
In the HSV infected mouse cornea peak numbers of neutrophils are
attained within 2 days after infection (5). Due to lack of chemotactic signals
resulting from the disruption of the normal IL-l signaling neutrophils failed to
attain peak numbers. These results are consistent with previous findings (8, 9)
including the most recent study conducted with IL-l ra Tg mice (11). It is
clearly evident that neutrophils are the critical early cellular mediators of HSK
pathogenesis, being involved in viral clearance (5, 6)

and possibly tissue

damage through the release of factors such as nitric oxide (25)or remodeling
factors such as matrix metalloproteinases (MMPs) (26). In addition,
neutrophils have also been considered as a source of molecules facilitating
angiogenesis or angiogenic factors themselves such as MMP-9 (26) and VEGF
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(27)

respectively,

and

thereby,

contributes

significantly

to

the

neovascularization process.
Many other cell types can be a potential source of angiogenic factors in
the cornea. These include the stromal fibroblast themselves; epithelial cells
and inflammatory cells such as macrophages (21). Possibly, with disease
progression, there is a shift in the source of angiogenic factors. In addition,
apart from VEGF (21), other angiogenic factors such as bFGF (our
unpublished results) or C-X-C chemokines such as MIP-2 (28) may be
involved in HSV induced corneal angiogenesis. The possibilities are
innumerable and presently unclear. Whatever the scenario, our results indicate
the effectiveness of IL-1 ra in blocking the overall angiogenesis process.
Similar results have been obtained in other murine models of corneal
angiogenesis (29).
The chronic inflammatory environment is maintained by the
angiogenic response, allowing further delivery of inflammatory cells. The
development of HSK lesions is dependent on this response, as shown in
studies that have targeted the corneal neovascular response early after virus
infection (7). One cell type crucial to HSK pathogenesis and presumably
delivered by newly formed (and therefore leaky) blood vessels is the CD4+ T
cell (3). Thus mice lacking CD4+ T cells, but possessing other components
normally required in pathogenesis, fail to develop HSK (3, 4). Consistent with
these reports, the lack of blood vessel development in the cornea of IL-1 ra
treated mice prevented the influx of CD4 + T cells. Thus part of the anti
inflammatory effects observed with IL-1 ra therapy also involved the
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impairment in the CD4+ T cell response. Hence, IL-I ra treatment targeted at
the early preclinical events also influenced subsequent clinical episodes in
HSK pathogenesis.
Finally and most importantly, results indicate that the activity of IL-I
needs to be kept under continuous check to achieve significant results. The
levels of IL-I in the cornea after an HSV infection remains elevated till around
day 9 p. i. (10). Thus the protocol aimed at abrogating IL-I activity for an
extended period of time produced the best results. Thus our results imply that
neutralizing the inflammatory milieu at an early time point may prove
beneficial in reducing the severity of HSK. This could be achieved by
blocking IL-I using IL-I receptor antagonist protein. Antagonizing the
proinflammatory environment abrogates the cascade of events that culminate
in HSK. Thus, targeting IL-I ra protein proved to be a worthwhile therapeutic
approach

for

successful

management

of

HSK,

a

blinding

immunoinflammatory lesion of humans.
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Fig 1. Following Subconjunctival injection, presence of IL-1 ra was
detectable in cornea for short period oftime.
At indicated time points, 6 corneas / group were processed for measuring
the human recombinant IL-I ra protein levels. Level of human
recombinant IL-I ra was estimated from supernatants of corneal lysates
of mice infected with 5xl06 pfu HSV-I RE by an antibody capture
ELISA as outlined in materials and methods. Results are expressed as
Mean ± SD of three separate experiments (6 corneas/time point).
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Figure 2: No difference in HSK score between locally administered IL-l ra
treated mice and vehicle control mice.
A. Interleukin-l receptor antagonist protein was administered
subconjunctivally 24 hr before corneal infection. Mean lesion HSK
score at day 20 p. i. of mice infected with 5xl06 pfu HSV-I RE. Each
dot represents the HSK score from one eye. Horizontal bars and
figures in the parenthesis indicate the Mean ± SD for each group.
Data is compiled from two separate experiments consisting of 8 eyes
in each group. * Statistically significant differences in mean HSK
score (p< 0.05) were observed between IL-I Ra Tg mice to either
vehicle control ~nd IL-I ra treated eyes.
B. Percentage severity of HSK score at day 20 p. i. of mice infected

with 5xl06 pfu HSV-I RE. Each vertical bar represents number of
eyes showing clinically evident lesions (HSK

score~

3). Data is

compiled from two separate experiments consisting of 8 eyes in each
group.
C. Mice were infected with 5xl06 pfu HSV-l RE. Mice were
terminated at day 20 p. i. and eyes were processed for paraffin
embedding. Hematoxylin and Eosin staining was carried out on 6J.!
sections. Magnification x 200.
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Fig 3. Mice treated with IL-J ra protein locally demonstrated similar
angiogenic response like vehicle control.
A.

Interleukin-1

receptor

antagonist

protein

was

administered

subconjunctivally 24 hr before corneal infection Kinetics of corneal
neovascularization process in mice infected with 5x106 pfu HSV-1 RE.
Angiogenesis scores were recorded as mentioned in the Materials and
Methods at indicated time points. Data is compiled from two separate
experiments involving 8 eyes per group and is expressed as Mean ± SD.
·Statistically significant differences in angiogenesis score (p< 0.05) were
observed between IL-1 Ra Tg mice to either vehicle control and IL-1 ra
treated eyes.
B. Angiogenesis scores for individual eyes of IL-1 ra treated , vehicle
control and IL-1 ra Tg mice infected with 5x106 pfu HSV-1 RE at day 20
p. i. Horizontal bars and figures show the mean for each group. Data are
compiled from two separate experiments consisting of 8 eyes per group.
C. At day 20 p. i. extensive growth of blood vessels can be seen in IL-1
ra treated and vehicle control mice infected with 5x106 pfu HSV -1 RE.
IL-1 Ra Tg mice show minimum angiogenic sprouts near the limbal ring
with the same dose.
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Fig 4. Human recombinant Interleukin-l

~eceptor

antagonist protein was

detected in mice receiving a combination of systemic and local
administration till day 7 post injection.
At indicated time points, 6 corneas / group were processed for measuring
the human recombinant IL-I ra protein levels. Level of human
recombinant IL-I ra was estimated from supernatants of corneal lysates
of mice infected with 5xI06 pfu HSV-I RE by an antibody capture
ELISA as outlined in materials and methods. Results are expressed as
Mean ± SD of three separate experiments (6 corneas/time point).
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Fig 5. Mice receiving IL-Z ra systemically in conjunction with local
administration demonstrated reduced HSK severity.
A.

Interleukin-l

receptor

antagonist

protein

was

administered

systemically along with subconjunctival injection 24 hr before corneal
infection as described in Materials and Methods. Mean lesion HSK score
at day 20 p. i. of mice infected with Sxl06 pfu HSV-l RE. Each dot
represents the HSK score from one eye. Horizontal bars and figures in
the parenthesis indicate the Mean ± SD for each group. Data is compiled
from two separate experiments consisting of 8 eyes in each group.

*,**

Statistically significant differences in mean HSK score (p< O.OS) were
observed between mice treated with either Smglkg body wt. !hr for 7 days

Sic + Imglcornea local (Group 1) or 2.5mgl kg body wt. Ihr for 7days
Sic + Imglcornea local IL-l ra and vehicle control.
B. Percentage severity of HSK score at day 20 p. i. of mice infected with
Sxl06 pfu HSV-l RE. Each vertical bar represents number of eyes
showing clinically evident lesions (HSK

score~

3). Data is compiled

from two separate experiments consisting of 8 eyes in each group.
C. Mice were infected with Sxl06 pfu HSV-l RE. Mice were terminated
at day 20 p. i. and eyes were processed for paraffin embedding.
Hematoxylin and Eosin staining was carried out on 6Jl sections.
Magnification x 200.
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Fig 6. Mice receiving a combination of systemic and local administration of
IL-I ra protein showed diminished angiogenesis following ocular infection.
A.

Interleukin-l

receptor

antagonist

protein

was

administered

systemically along with subconjunctival injection 24 hr before corneal
infection as described in Materials and Methods. Kinetics of corneal
neovascularization process in mice infected with 5x106 pfu HSV-1 RE.
Angiogenesis scores were recorded as mentioned in the Materials and
Methods at indicated time points. Data is compiled from two separate
experiments involving 8 eyes per group and is expressed as Mean ± SD.*
Statistically significant differences in angiogenesis score (p< 0.05) were
observed between mice treated with either 5mglkg body wt. Ihr for 7days

SIc + Imglcornea local or 2.5mgl kg body wt. Ihr for 7days SIc +
1mglcornea local IL-1 ra and vehicle control.
B. Angiogenesis scores for individual eyes of IL-l ra treated, vehicle
control and IL-1 ra Tg mice infected with 5x10?pfu HSV-1 RE at day 20
p. i. Horizontal bars and figures show the mean for each group. Data are
compiled from two separate experiments
C. At day 20 p. i. extensive growth of blood vessels can be seen in IL-1
ra treated and vehicle control mice infected with 5x106 pfu HSV -1 RE.
IL-1 ra treated mice show minimum angiogenic sprouts near the limbal
ring. In comparison, vehicle control eyes demonstrated extensive growth
of blood vessels with the same dose.
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Fig 7. Presence of abundant Gr-l+ve cells in the cornea of vehicle control
mice but not in IL-l ra treated mice at 48 hr p. i.
Single cell suspensions of corneal cells were prepared from 4 eyes at 48
hr p. i. The cells were counted and stained with FITC labeled anti Gr-l
antibody .and numbers of Gr-l positive cells were enumerated by FACS.
Dotplot is representative of one of three separate experiments. The
number on the upper right corner represents the percentage of Gr-l + cells
of total corneal cells at 48 hr. p. i.
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Fig 8. Diminished CD.r T cell influx in mice treated with IL-l ra protein.
A. Single cell suspensions of corneal cells were prepared from 4 eyes at
day 20 p. i. The cells were counted and stained with FITC labeled anti
CD4+ antibody and numbers of positive cells were enumerated by FACS.
Isotype control was used as negative control. Dot plot is the
representative of one of three separate experiments. Numbers on the
upper right comer represents the percentage of CD4+ T cells of total
gated lymphocytes at day 20 p. i..
B. At day 20 p. i., representative eyes were taken and snap frozen in
OCT compound and 6J.l sections were cut. The sections were stained for
CD4+T cells using an FITC labeled anti CD4+antibody as described in
Materials and Methods.

Corneas were mounted with Vectashield

mounting medium for fluorescence with Propidium Iodide and
visualized under a microscope. The white arrows indicate the CD4+ T
cells in the corneas.
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Fig 9. IL-1 ra treated mice demonstrated reduced protein levels of IL-6,
MIP-2 and VEGF.
A, B & C. At indicated time points, 6 corneas /group were processed for
measuring the IL-6, MIP-2 and VEGF protein levels. Levels of IL-6,
MIP-2 and VEGF was estimated from supernatants of corneallysates of
mice infected with 5xl06 pfu HSV-l RE by an antibody capture ELISA
as outlined in materials and methods. Results are expressed as Mean ±
SD of three separate experiments (6 corneas/time point). ·Statistically
significant differences in IL-6, MIP-2 and VEGF level (p< 0.05) were
observed between IL-l ra treated mice to vehicle control mice.
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PART VI

A NOVEL FLOW CYTOMETRY BASED
ASSAY FOR QUANTIFICATION OF
CORNEAL ANGIOGENESIS IN THE MOUSE
MODEL OF HERPETIC STROMAL
KERATITIS
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Research described in this chapter is a slightly modified version of an article
published in 2005 in Experimental Eye Research by Partha Sarathi Biswas,
Kaustuv Banerjee, Bumseok Kim, Jordan Smith and Barry T. Rouse.

Biswas, P. S., K. Banerjee, B. Kim, J. Smith, and and B. T. Rouse. 2005. A
novel flow cytometry based assay for quantification of corneal angiogenesis in
mouse model of herpetic stromal keratitis. Exp. Eye Res. 80(1):73. Copyright
2004. The American Association ofImmunologists, Inc.

In this chapter "we" and "our" refers to co-authors and me. My contributions
in the paper include (1) selection of the topic (2) data analysis and
interpretation (3) planning experiments (4) compiling and interpretation of the
literature (5) understanding how results fit with the literature (7) compilation
of contributions into one paper (8) providing structure to the paper (9) making
graphs, figures and tables (10) writing and editing.

ABSTRACT
In this study a novel flow cytometry based quantitative assay for measuring
corneal angiogenesis is demonstrated. Corneas of Balb/c mice were lightly
scarified and infected with 5xl05 , 5xl04 and 5xl03 pfu HSV-l RE virus.
Development of corneal angiogenesis was studied on day 15 post infection by
direct visualization of infected cornea with a slit-lamp biomicroscope.
Endothelial cells constituting the newly developed blood vessels in cornea
were stained with murine anti CD31 antibody on frozen corneal sections and
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corneal whole mounts at day 15 p. i. Total number of endothelial cells was
quantified at day 15 post infection by flow cytometry. Mice infected with
different doses of HSV-1 RE developed severe to mild corneal angiogenesis at
day 15 p. i. Endothelial cells constituting the newly formed blood vessels
expressed CD31 at day 15 post infection. Flow cytometry revealed that, the
number of CD31 positive cells isolated from diseased corneas increased with
the increase in Neovascularization index. The flow cytometry analysis used in
this present study is a useful, accurate and cost effective method for
quantifying corneal angiogenesis.

INTRODUCTION
Herpetic stromal keratitis (HSK) is an immunoinflammatory lesion in the
corneal stroma that ensues from ocular infection with Herpes simplex virus
(HSV) (1). Studies in murine models have revealed a complex pathogenesis,
involving multiple molecular and cellular events (2). One of these is
neovascularization of the normally avascular cornea. New blood vessels sprout
from vessels at the corneal lilnbus within 24 h of HSV infection (3), and
eventually extend to the central cornea within the next 10-15 days (3). Such
angiogenesis impairs vision and appears necessary for the ingress of T cells
responsible for orchestrating HSK (2). Measuring corneal angiogenesis is
normally accomplished by direct visualization with a slit-lamp biomicroscope
and recording the area occupied by new vessels (4). This technique is tedious
and subject to error especially when performed on living animals. In addition
the approach fails to account for any difference in the vessel thickness. Other
217

techniques, including ultrasound micro-imaging and other microimaging
technologies (5, 6) for angiogenesis quantification have been used but these
require sophisticated instrumentation and trained personnel.
In this report, an alternative approach for the quantification of corneal
angiogenesis using a flow cytometry based assay is presented. Our results
indicate that, following HSV infection endothelial cells constituting the newly
formed blood vessels in corneal stroma express CD31 (PECAM 1). By
targeting this surface marker by a fluorescently labeled antibody, number of
endothelial cells in inflamed murine cornea could be quantified. The numbers
of CD31 + cells were proportional to the growth of blood vessels in the infected
cornea, as measured by biomicroscopy. In addition, number of CD31 +
cell/cornea correlated with the angiogenic score. The flow cytometry based
assay efficiently discriminated the difference in angiogenic response between
mice infected with different doses of virus. Thus, estimation of angiogenesis
on the basis of number of endothelial cells proved to be a potential technique
for the quantification of corneal neovascularization.

MATERIALS AND METHODS
Mice
Wild type female 6 to 8 weeks old Balb/c mice were purchased from Harlan
Sprague-Dawley (Indianapolis, Indiana). Animals were sex and age matched
for all experiments. To prevent bacterial superinfections, all mice received
prophylactic treatment with Sulphatrim pediatric suspension (Barre-National
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Baltimore, MD). All experimental procedures were in complete agreement
with the Association for Research in Vision and Ophthalmology (ARVO)
resolution on the use of animals in research.

Virus
HSV-l RE (obtained from Dr. Robert Hendricks Laboratory, University of
Pittsburgh School of Medicine) was used in the present study. The virus was
propagated and titrated on monolayer of Vero cells (ATCC, Cat No. CCL81)
using standard protocols (7). Infected Vero cells were harvested, titrated and
0

stored in aliquots at _80 C until used.

Corneal HSV -1 infection
Corneal infections of all mice groups were conducted under deep anesthesia
induced by intraperitoneal injection of Avertin (Sigma, St. Louis, MO). Mice
were scarified on their corneas with a 27 -gauge needle and a 4JlI drop
containing the required dose of virus (5x105, 5xl04 and 5xl03 pfu) was
applied to the eye and gently massaged with the eyelids.

Angiogenesis Scoring
The eyes were examined on day 15 post infection by a slit-lamp
biomicroscope (Kowa Co. Nagoya, Japan) and angiogenesis severity was
measured as described previously (4). Briefly, a grade of 4 for a given
quadrant of the circle represents a centripetal growth of 1.5mm toward the
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corneal center. The score of the 4 quadrants of the eye were then summed to
derive the Neovascularization (NV) index (range 0-16) for each eye.

Confocal Microscopy
For immunohistochemistry, at day 15 p. i. eyes were frozen in optimum
cutting temperature (OCT) compound (Miles, Elkart, IN). Six-micron-thick
sections were cut, air dried, and fixed in cold acetone for 10 min at _20 0 C.
The sections were blocked with 3% BSA (Sigma) containing unconjugated
anti-CDI6/32 (1:200) antibody (Pharmingen, San Diego, CA) for 2 hour at
37 0 C. For detection of endothelial cells in the stroma, the sections were
incubated with FITC-coupled monoclonal anti-mouse CD31 antibody (anti
mouse PECAMl) (Clone MECI3.3, Pharmingen) at a concentration of 1:500
in 1% BSA at 4°C overnight. Corneas were repeatedly washed in PBS and
then mounted with Vectashield mounting medium for fluorescence with
Propidium Iodide (Vector Laboratories Inc, Burlingame, CA) and visualized
with a confocal microscope (Leica, Wetzlar, Germany).

Immunofluorescence staining of blood vessels on corneal whole mounts
Immunohistochemical staining for vascular endothelial cells was also
performed on corneal flatmounts. At day 15 p. i. corneas from infected mice
were dissected under stereo-microscope (Leica, Wetzlar, Germany). Then
corneal wholemounts were rinsed in PBS for 30 minutes and flattened on a
glass slide under stereo-microscope (Leica, Wetzlar, Germeny). Corneal
flatmounts were dried and fixed in 100% acetone (Sigma, St. Louis, MO) for
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10 minutes at -20 0 C. Nonspecific binding was blocked with 5% BSA (Sigma)
containing unconjugated anti-CDI6/32 (1:200) antibody (Pharmingen) for 2
hour at 37 0 C. Incubation with FITC-coupled monoclonal anti-mouse CD31
antibody (anti mouse PECAMl) (Clone MECI3.3, Pharrningen) at a
concentration of 1:250 in 1% BSA at 4 0 C overnight was followed by
subsequent washes in PBS at room temperature. Corneas were mounted with
Vectashield mounting medium for fluorescence with Propidium Iodide
(Vector Laboratories Inc, Burlingame, CA) and visualized with a fluorescence
microscope (Leica, Wetzlar, Germany).

Flow Cytometry
Mice were infected with different doses of HSV-l RE. At day 15 p. i.,
N eovascularization index of individual eyes were determined by direct
visualization of infected corneas with slit-lamp biomicroscope. Two corneas
with similar NV index were pooled together and stained for number of CD31 +
cells/cornea. This was repeated three times.
In another set of experiments, three groups of mice were infected with
5xl05, 5xl04 and 5xl03 pfu HSV-l RE. At day 15 p. L, NV index of
individual eyes were determined by direct visualization of infected corneas
with slit-lamp biomicroscope. Two corneas with a NV index and closest to the
Mean NV index of that group were pooled together and stained for number of
CD31 + cells/cornea. This experiment was repeated thrice.

Staining procedure: Corneas were dissected carefully under a stereo
microscope (Leica, Wetzlar, Germany). All precautions were taken to avoid
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the limbal blood vessels. Single-cell suspensions were prepared from 2
corneas at day 15 post infection as described elsewhere (8), with some
modifications. Briefly, corneal buttons were incubated with collagenase D
(Roche) for 60 min at 37°C in a humidified atmosphere at 5% C02. After
incubation, corneas were disrupted by grinding with a syringe plunger and
passing through a cell strainer. Cells were washed and suspended in RPMI
1640 with 10% FBS and counted by Trypan Blue staining. The Fe receptors on
the cells were blocked with unconjugated anti-CD 16/32 (Pharmingen) for 30
min. Samples were incubated with FITC labeled anti CD31 antibody (Clone
MECI3.3, Pharmingen) and isotype controls for 30 minutes. All samples were
collected on a FACScan (BD Biosciences, San Diego, CA), and data were
analyzed using CellQuest 3.1 software (BD Biosciences, San Diego, CA).

Statistical Analysis
Data obtained were analyzed for statistical significance by Student's t test.
Pearson's Product Moment Correlation Coefficient was used to determine
correlation coefficient.

RESULTS
Endothelial cells constituting the newly developed blood vessels express
CD31 (PECAM 1) following corneal HSV-1 infection.
Endothelial cells making up the newly formed blood vessels are characterized
by the expression of adhesion molecules such as CD31 (PECAM 1), Vascular
endothelial - cadherin (VE-cad) and von Willebrand factor (9). Expression of
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these surface molecules on endothelial cells are regulated by inflammatory
mediators (10, 11). To find out whether endothelial cells constituting the
newly developed blood vessels express CD31, corneas of infected mice were
stained for CD31. As demonstrated in Fig. 1A, endothelial cells making up the
newly grown blood vessels in corneal stroma expressed CD31 (PECAM 1) at
day 15 p. i. In addition, fluorescently labeled anti CD31 antibody stained the
blood vessels on corneal whole mounts at the same time point (Fig. IB). Thus,
targeting CD31 with a fluorescently coupled antibody may prove to be a
reliable and efficient tool to label and quantify the number of endothelial cells
in corneal angiogenesis.

Increase in the number of CD31 + cells is associated with the increase in
Neovascularization (NV) index
At day 15 p. i., the NV index of individual eyes was determined by slit-lamp
biomicroscopy. Two corneas with similar NV index were pooled together and
the nUlnber of CD31 + cells was counted by FACS analysis. As demonstrated
in Fig 2A, 2B and 2C, corneas with higher NV index have more CD31 +
cells/cornea. In contrast to naIve cornea, there was a gradual increase in the
number of CD31 + cells/cornea with the increase in NV index. In addition, a
strong correlation (r = 0.965,

p~

0.0002) was observed between NV index and

number of CD31 + cells/cornea. Isotype control showed no background
staining. Greater than 65% of mouse brain endothelial cells (positive control)
stained positive for CD31 (data not shown). Overall, this experiment revealed
that, the cell based assay closely resemble the NV index obtained by direct
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visualization of infected cornea at day 15 p. L

Difference in the number of CD31 + cells/cornea in mice infected with
different doses of virus
Three groups of mice were infected with 5xl05 pfu, 5xl04 pfu and 5xl03 pfu
HSV-l RE respectively. At day 15 p. L, the NV index of individual eyes was
scored by slit-lamp biomicroscopy. As shown in Fig. 3, groups of mice
infected with 5xl05 pfu, 5xl04 pfu and 5xl03 pfu HSV-l RE had mean NV
index of 10.7, 5.6 and 1.8 respectively. Mean NV index of mice infected with
5xl05 pfu was significantly (p< 0.05) higher than mean NV index of mice
infected with 5xl04 and 5xl03 pfu virus. Two eyes from each group with NV
indexes close to the group mean were pooled together and number of CD31 +
cells/cornea were quantified using flow cytometry. Once again there was a
concordance between the two assays. Group infected with the highest dose
(5xl05 pfu) and showing higher mean NV index h~ve significantly (p< 0.05)
greater number of CD31 + cells/cornea (18,365

± 3499) in comparison to 5xl04

pfu (925 ± 478) and 5xl03 pfu (130 ± 61) (Fig. 4A, B and C). Thus in
comparison with the average number of endothelial cells/cornea, mice infected
with 5xl05 pfu have approximately 20 fold (5xl04 pfu) and 200 fold (5xl03
pfu) more CD31 + cells/cornea.

DISCUSSION
In this study a novel flow cytometry based assay was used to quantify corneal
angiogenesis following ocular HSV infection. Our results indicate that,
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endothelial cells constituting the newly fonned blood vessels in corneal stroma
express CD31 (PECAM 1) at day 15 post infection. Thus, labeling the blood
vessel endothelial cells by targeting this surface marker provided a unique
opportunity to quantify the number of endothelial cells/cornea. The data
revealed that, the number of CD31 + cells/cornea was proportional to the
growth of blood vessels in infected cornea. In addition, this assay was able to
pick up the difference in angiogenic response between mice infected with
different doses of virus. Thus, estimation of angiogenesis on the basis of
number of endothelial cells proved to be a useful approach to quantify corneal
neovascularization.
Strongly woven endothelial cells on cellular matrix make up the wall
for blood vessels. With the increase in length, thickness and number of
vasculature, increase in the number of endothelial cells constituting the newly
developed vessels were expected. Thus, quantifying the number of endothelial
cells would directly reflect the amount of blood vessels present in the corneal
tissue at a particular time point. By the virtue of this assay, we were able to
consider the three-dimensional structure i.e. length, width and height of a
blood vessel instead of relying on the visualization of surface vasculature
during the process of quantification by conventional way.
As evident from our study, the cell-based assay was responsive enough
to detect the gradual increase in the number of endothelial cells with the
increase in NV index. To our knowledge, this is the first report where the
growth of blood vessels has been successfully represented by a cell-based
assay. In addition, this assay was able to differentiate the angiogenic response
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observed following infection with various doses of virus. However, the flow
cytometry based assay for quantification of corneal angiogenesis has some
shortcomings. These include the fact that, this is a terminal assay and cannot
be used for angiogenesis kinetics study. Besides this, in case of naIve mice, in
spite of an absence of an angiogenic score, still approximately 0.1 % of cells
were CD31 +. We believe that this discordance was attributed to the underlined
corneal endothelium layer. Adding up, was the possibility of overestimation
due to possible contamination of limbal blood vessel endothelial cells.
Currently we are in the process of overcoming these constraints to make it
more accurate and reliable.
In this report,

we demonstrated an alternative approach of

quantification of corneal angiogenesis in mouse model of HSK. The cell based
technique closely resembled the commonly used method to quantify corneal
angiogenesis. It would be of particular interest to know whether this flow
cytometry technique is useful in assessing angiogenesis in other corneal
inflammatory models and tumor systems. Overall, estimation of angiogenesis
on the basis of number of endothelial cells may be a potential technique for the
quantification of corneal neovascularization.
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Fig 1. Endothelial cells constituting the new blood vessels in corneal stroma
express CD31 at day 15 post infection.
A. At day 15 p. i. eyes were frozen in OCT compound and six micron
sections were made. The slides were stained with monoclonal anti mouse
CD31 primary antibody and biotinylated anti rat IgG secondary
antibody. Diaminobenzidine was used as substrate, and sections were
counterstained with hematoxylin. Original magnification x200. The
black arrow (inset) indicates the cross section of endothelial cells lining
the lumen of a blood vessel in the corneal stroma.
B. At day 15 p. i. eyes were frozen in OCT compound and six micron
sections were made. The slides were stained with FITC-coupled
monoclonal anti mouse CD31 antibody. The slides were counterstained
with Propidium Iodide and visualized under a Leica SP2 Laser scanning
confocal microscope (Leica, Wetzlar, Germany). The white arrow (inset)
indicates the cross section of endothelial cells lining the lumen of a
blood vessel in the corneal stroma.
C. Immunohistochemical staining for vascular endothelial cells was
performed on corneal flatmounts at day 15 post infections with FITC
coupled monoclonal anti-mouse CD31 antibody. Corneas were mounted
with an anti fading agent containing Propidium Iodide and visualized
with a Leica SP2 Laser scanning confocal microscope (Leica, Wetzlar,
Germany). Extensive neovascularization was observed from limbal
blood vessels at day 15 post infection. NaIve mice showed little or no
angiogenic sprouts near the limbal ring. The solid and double white
231

arrows indicate the limbal blood vessel and newly grown blood vessel in
the cornea respectively.
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Fig 2. Increase in the number of CD31+ cells is associated with heightened
angiogenic response following corneal micropocket assay.
Hydron pellets (black arrow) containing VEGF (200 ng) were implanted
into the corneal pockets (n=6). Control mice received pellets only. At
day 4 post implantation angiogenic response was assessed. Two corneas
demonstrating similar angiogenic response were pooled together and
number of CD31 + cells was enumerated by FACS analysis as described
in Materials and Methods. The dot plot represents one of the three
separate experiments. The number in the right hand comer represents
percentage of CD31 + cells.
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Fig 3. Increase in the number of CD31+ cells is associated with the increase
in NV index at day 15 p. i.
A. Mice were infected with different doses of HSV-l RE (5xl0 5 pfu,
5xl04 pfu and 5xl03 pfu). Individual eyes were scored for angiogenesis
(NV index) with slit lamp bio-microscope at day 15 p. i. Two corneas of
same NV index were pooled together and stained with FITC labeled
CD31+ antibody. A total volume of 100)l1 cell suspension containing 5xl04
cells was spinned down. The slides were counterstained with Propidium
Iodide and visualized under a microscope (Leica, Wetzlar, Germany).
Original magnification x200
B. Mice were infected with different doses of HSV-1 RE (5xl0 5 pfu, 5xl04
pfu and 5xl03 pfu). Individual eyes were scored for angiogenesis (NV
index) with slit lamp bio-microscope at day 15 p. i. Two corneas of same
NV index were pooled together and number of CD31 + cells was
enumerated by FACS analysis as described in Materials and Methods. The
dot plot represents one of the three separate experiments. The number in
the right hand comer represents percentage of CD31 + cells.
C. Blood vessel development of representative eyes with various NV
index. Photographs were taken at day 15 p. i. before FACS analysis.
Representative eyes with NV index of 14 demonstrated extensive blood
vessel development, whereas eyes with NV index of 2 show minimal
blood vessel development.
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D. The line diagram represents a steady increase in the number of CD31 +
cells/cornea with the increase in NV index. The data is accumulated from
three separate experiments and expressed as Mean ± SD.
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Fig 4. Mice infected with higher dose of virus demonstrated increased
number of CD31 + cells/cornea at day 15 p. i.
A. Three groups of mice (n = 8) were infected with 5xl05 pfu, 5xl04 pfu
and 5xl03 pfu of HSV-l RE respectively. Individual eyes were scored
(NV index) for angiogenic response at day 15 p. i. with a slit lamp
biomicroscope. Two corneas/group having a NV index closest to the
mean NY index of that group were pooled together and number of
CD31+ cells was enumerated by FACS analysis as described in Materials
and Methods. The dot plot represents one of the three separate
experiments. The number in the right hand comer represents percentage
of CD31 + cells.
B. Blood vessel development of representative eyes with various NV
index. Photographs were taken at day 15 p. i. before FACS analysis.
Representative eyes from different groups showing variable degree of
angiogenic response at day 15 p. i.
C. The bar diagram represents the number of CD31 + cells/ cornea at day
15 p. i. Figure in the parenthesis indicate the Mean NV index for each
group. * Significant difference (p<0.05) in comparison to 5x10 4 and
5xl0 3 pfu.
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